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Abstract  
Senescence is an important tumour suppressor mechanism, which prevents the proliferation 
of stressed or damaged cells. The use of RNA interference to identify genes with a role in senescence 
is an important tool in the discovery of novel cancer genes. In this work, a protocol was established for 
conducting bypass of senescence screenings, using shRNA libraries together with next-generation 
sequencing. Using this approach, the SWI/SNF subunit Arid1b was identified as a regulator of cellular 
lifespan in MEFs. SWI/SNF is a large multi-subunit complex that remodels chromatin. Mutations in 
SWI/SNF proteins are frequently associated with cancer, suggesting that SWI/SNF components are 
tumour suppressors.  
Here the role of ARID1B during senescence was investigated. Depletion of ARID1B extends 
the proliferative capacity of primary mouse and human fibroblasts. Furthermore, in cells expressing 
mutant RASG12V and PIK3CAH1047R, ARID1B is necessary for the maintenance of oncogene-induced 
senescence (OIS). Knockdown of ARID1B during OIS results in reduced expression of the CKIs 
p21Cip1 and p16INK4a. Many SWI/SNF proteins are post-transcriptionally induced during both replicative 
senescence and OIS, suggesting a broader role for the SWI/SNF complex in senescence.  
Ectopic expression of components of the SWI/SNF complex induced premature senescence 
associated with an increase in p21Cip1 and p16INK4a protein levels. SILAC analysis of global changes in 
protein levels identified enrichment of mitochondrial proteins and depletion of mitotic proteins upon 
ARID1B expression.  Mitochondrial dysfunction and ROS production are important in ARID1B 
expressing cells as growth arrest was rescued using antioxidant N-acetyl-cysteine. Finally, analysis of 
cancer genome sequencing data has identified ARID1B as a mutational-driver gene in some cancers. 
In these tumours, ARID1B mutations are often associated with mutations in TP53 and PTEN. 
Altogether the present evidence suggests that regulation of senescence by different mechanisms 
contributes to explain the tumour suppressive properties of the SWI/SNF complex. 
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Chapter 1. Introduction 
 
1.1. Senescence  
 
Cellular senescence was first described by Hayflick and Moorhead when they observed normal human 
diploid cells divide a limited number of times before undergoing a permanent growth arrest they 
termed senescence (Hayflick and Moorhead, 1961). Despite a loss of proliferative capacity, senescent 
cells remain viable and metabolically active; they do not express genes required for proliferation even 
under strong mitogenic conditions, thereby distinguishing the process from quiescence (Hayflick, 
1965). Senescence is an intrinsic cellular mechanism, which like apoptosis, is activated by a variety of 
cell stresses, including oxidative damage, oncogene activation, and telomere shortening. Senescence 
prevents harmful lesions acquired in cells from being passed on to daughter cells (Figure 1.1).  
 
Although differences exist depending on the stimuli and the cell type in which senescence is studied, 
the ARF/p53 and p16INK4a/retinoblastoma (RB1) pathways are crucial to senescence activation (Shay 
et al., 1991). The tumour suppressors RB1 and p53 are frequently lost in cancer. This along with the 
understanding that normal cells senesce in response to oncogenic stress led to the hypothesis that 
senescence is an important tumour suppression mechanism, preventing the proliferation of stressed 
or damaged cells (Chen et al., 2005; Collado et al., 2005). Cellular senescence can oppose neoplastic 
progression in vivo and escape from senescence, or immortality, is important for malignant 
transformation (Dimri, 2005).  
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As well as having a distinct morphological phenotype, the expression of many cell cycle genes is 
altered during senescence (Mason et al., 2004; Shelton et al., 1999). This includes the up-regulation 
of important cyclin-dependent kinase inhibitors (CDIs) CDKN1a and CDKN2a (encoding p21Cip1 and 
p16INK4a respectively) and the repression of proteins involved in S-phase entry such as cyclin A, cyclin 
B and proliferating cell nuclear antigen (PCNA) (Pang and Chen, 1994; Seshadri and Campisi, 1990; 
Stein et al., 1991). The repression of these genes is predominantly due to the unphosphorylated 
status of RB1 in senescent cells, thereby allowing RB1 to repress the expression of E2F target genes 
by binding to E2F and inhibiting its activity. (Futreal and Barrett, 1991; Stein et al., 1990). 
 
Amongst the most notable changes in gene expression during senescence is the up-regulation of 
multiple secreted factors, which collectively account for the SASP (Coppe et al., 2010; Shelton et al., 
1999). Through the SASP, senescent cells influence their surrounding microenvironment (Acosta et 
al., 2013; Coppe et al., 2008). Depending on the context, these secreted factors can have tumour 
promoting or tumour suppressive effects (Krtolica et al., 2001).  
 
The most widely used assay for identifying senescent cells is the detection of perinuclear β-
galactosidase activity (Figure1.2) (Courtois-Cox et al., 2008; Dimri et al., 1995). SA-β-Gal is a 
consequence of increased lysosomal mass in senescent cells, which allows SA-β-Gal activity to be 
detected at a sub-optimal pH of pH 6.0, as opposed to the optimal pH of 4.0-4.5 (Kurz et al., 2000; 
Robbins et al., 1970). This increase in β-galactosidase activity can be detected in cultured cells or in 
vivo either by the breakdown of a chromogenic substrate 5-bromo-4-chloro-3-indolyl β-d-
galactopyranoside (X-Gal) or by the breakdown of fluorescein-di-β-d-galactopyranoside (C12FDG)  
(Debacq-Chainiaux et al., 2009; Dimri et al., 1995). A positive SA-β-Gal reaction can also be seen in 
non-senescent cells and is induced by high confluency and serum starvation in tissue culture 
(Severino et al., 2000); thus SA-β-Gal must be used in combination with other senescence markers to 
affirm the senescence phenotype. 
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Senescent cells also display an increase in the size of autophagic vacuoles (Gerland et al., 2003). 
Autophagy, a lysosome dependent cellular process, is involved in the digestion of the cell’s organelles 
and like senescence it is activated in response to stress (Hoare et al., 2011). In 2009 Young et al., 
demonstrated that autophagy associated genes are upregulated during senescence, and the inhibition 
of autophagy can delay the onset of senescence (Young et al., 2009). Recent work from the same 
group revealed that the cell’s endomembrane system is reorganised to spatially couple lysosomes and 
mTOR forming a complex called the TOR-autophagy spatial coupling compartment (TASCC). The 
TASCC resides a short distance from the Golgi apparatus and supports the up-regulation of protein 
synthesis during senescence (Narita et al., 2011).  
 
Nuclear architecture also changes during senescence  (O'Sullivan and Karlseder, 2012). Chromatin in 
the nucleus is reorganised to include specific regions of heterochromatin termed SAHF (Narita et al., 
2003b). These structures can be visualised as DAPI stained foci (Figure 1.2). SAHFs have recently 
been shown to possess a higher order structure consisting of distinct layers of repressive histone 
marks, H3K9me3 forming the core of the SAHF with a H3K27me3 outer ring (Chandra et al., 2012). 
The formation of SAHFs requires co-operation between many proteins including heterochromatin 
protein 1 (HP1), histone H2A variant macroH2A, high mobility group A (HMGA) proteins, histone 
repressor A (HIRA) and anti-silencing function 1a (ASF1a) (Zhang et al., 2007). These 
heterochromatic structures are important in silencing E2F target genes to halt cell cycle progression 
(Narita et al., 2003a). Knockdown of proteins required for SAHF formation, such as ASF1a or HMGA1 
can delay senescence (Narita et al., 2006; Zhang et al., 2005). 
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human tissues (Takubo et al., 2010). Replicative senescence, triggered by telomere shortening is 
sensed as a double-strand break (DSB) initiating a DDR via p53 activation. (Garcia-Cao et al., 2006). 
The DDR can also be activated by telomere “uncapping” which occurs when the protective structure 
capping telomeric overhangs is disrupted (Blackburn, 2001; Takai et al., 2003). 
 
In humans, cells which are required to divide indefinitely, such as certain stem cells and in somatic 
cells of other species, such as mice, telomeric overhangs are maintained by elevated expression of 
the ribonucleoprotein enzyme telomerase (Greider and Blackburn, 1985; Mathon et al., 2001; Shi et 
al., 2002). Telomerase is able to extend the 3’ end of telomeres preventing the DDR that results from 
telomere shortening. Immortalised human cell lines and multiple human tumours overexpress 
telomerase, suggesting that telomerase expression is important in avoiding senescence and in the 
development of tumours (Counter et al., 1992; Morin, 1989). A clear link between telomerase and 
senescence was established when the introduction of telomerase in human epithelial cells and 
fibroblasts resulted in an extension of lifespan (Bodnar et al., 1998). 
 
1.1.3. Stress-induced senescence  
Senescence can also be induced as a stress response independent of the replicative state. These 
responses are termed ‘stress-induced senescence’ or ‘premature senescence’ as it occurs before full 
telomeric attrition has taken place and is characterised by a more rapid onset of senescence (Ben-
Porath and Weinberg, 2005). Stimuli which induce premature senescence include aberrant oncogene 
activation or the use of chemotherapeutic drugs (Kuilman et al., 2010). Oxidative stress can also 
induce premature senescence. For example, mouse embryonic fibroblasts (MEFs) that express 
telomerase maintain a long telomere length (~50 kb compared to ~10kb in humans), however still 
undergo senescence relatively rapidly when propagated in culture (Itahana et al., 2004; Rangarajan 
and Weinberg, 2003). This ‘culture shock’ is attributed to non-physiological levels of oxidative stress 
that results in a DDR (Parrinello et al., 2003; Sherr and DePinho, 2000). 
25   
The most commonly studied form of premature senescence, is that elicited by aberrant oncogene 
activation, termed oncogene-induced senescence (OIS) (Courtois-Cox et al., 2008). In 1997 Serrano 
et al., demonstrated that overexpression of a constitutively active form of H-RAS (RASG12V) triggered 
premature senescence (Serrano et al., 1997). Similarly overexpression of the downstream effectors of 
RAS, such as BRAF and MEK also induced senescence (Lin et al., 1998; Zhu et al., 1998). During 
OIS a rise in p16INK4a and p53 provide negative feedback regulation to prevent uncontrolled 
proliferation (Ohtani et al., 2001; Serrano et al., 1997; Wei et al., 2001). Furthermore, unregulated 
RAS signalling creates a surplus of mitogenic signals that leads to hyper-replication, triggering a DDR 
(Bartkova et al., 2006; Di Micco et al., 2006). The discovery that many different types of benign lesions 
contain senescent cells and that these cells decrease in number during malignant transformation has 
revealed the importance of OIS as a barrier to tumourigenesis in vivo (Table 1.1 and Figure 1.3). 
 
Table 1.1. Senescent cells are found in pre-malignant lesions in vivo. 
Lesion Reference 
Human melanocytic nevi (Gray-Schopfer et al., 2006; Michaloglou et al., 2005) 
Murine lung adenomas (Collado et al., 2005; Dankort et al., 2007) 
Human dermal neurofibromas (Courtois-Cox et al., 2006) 
Human and murine prostate PIN lesions (Chen et al., 2005) 
Murine pancreatic intraductal neoplasias (Collado et al., 2005) 
Murine papillomas (Collado et al., 2005) 
Murine lymphomas (Braig et al., 2005) 
Early murine melanomas (Ha et al., 2007) 
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numerous reports have used rapamycin to inhibit mTOR and bypass OIS in human fibroblasts 
(Demidenko et al., 2009b; Kolesnichenko et al., 2012).  
Reprogramming of somatic cells into induced Pluripotent Stem cells (iPS) can be achieved by the 
expression of four transcription factors, OCT4, SOX2, KLF4 and c-MYC (Takahashi and Yamanaka, 
2006). Interestingly the early response to expression of the reprogramming factors induces a 
senescence arrest coupled to the induction of the DDR and the upregulation of senescence markers 
such as p16INK4a, p53 and p21CIP1, suggesting senescence is a barrier to efficient iPS reprogramming 
(Banito et al., 2009; Hong et al., 2009; Li et al., 2009). The theory that the majority of a tumour mass 
arises from just a few cells termed cancer stem cells (CSCs), with the ability to self-renew and that 
cancer cells may trans-differentiate to migrate or form tumour-associated vasculature, has highlighted 
the importance of this senescence barrier in preventing cells attaining unlimited self-renewal 
properties in a tumour setting (Reya et al., 2001). 
 
Analogous to excessive oncogene activation, loss of tumour suppressor signalling can also activate a 
senescence response; generally via the unconstrained activation of downstream oncogenes. The 
PTEN tumour suppressor protein is an inhibitor of PI3K and is mutated in many cancers (Li et al., 
1997; Liaw et al., 1997). PTEN null MEFs have a rapid onset of senescence dependent on p53 
activation (Chen et al., 2005). Similarly, loss of NF1, a RAS GTPase activating protein (GAP), results 
in excessive RAS signalling, triggering a negative feedback loop in human fibroblasts activating OIS 
(Bollag et al., 1996; Cichowski et al., 2003; Courtois-Cox et al., 2006). 
 
1.1.4. Molecular mechanisms regulating senescence 
As mentioned previously, the ARF/p53 and the p16INK4a/RB1 pathways are central to the induction and 
maintenance of senescence (Figure 1.4) (Sherr and McCormick, 2002). Disruption of both of these 
pathways in humans results in extension of replicative lifespan in normal cells (Shay et al., 1991). In 
mouse embryonic fibroblasts (MEFs) the critical pathways controlling senescence operate via p53, 
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with Rb1 having a less important regulatory role (Harvey et al., 1993). Inactivation of either p53 or 
p19ARF results in a bypass of senescence in MEFs, with these cells maintaining a high proliferative 
potential (Kamijo et al., 1997). A similar proliferative advantage is seen in triple-knockout MEFs where 
Rb1, p107 and p130 pocket proteins are all inactivated; suggesting that in mice Rb1 function may be 
compensated by related proteins (Sage et al., 2000). The p53 and RB1 pathways converge under 
particular cell stresses, the functional outcome of these pathways is the activation of various CDKIs 
that prevent cell cycle progression, and at high levels result in a permanent growth arrest (Alcorta et 
al., 1996; Stein et al., 1999).  
 
P53 is activated under a number of different cell stresses, including replicative senescence, OIS, 
oxidative damage and the addition of cytotoxic drugs (Vousden and Lu, 2002). In response to DNA 
damage, p53 is phosphorylated by DDR kinases ATM/Chk2 and ATR/Chk1 (Hirao et al., 2000; Liu et 
al., 2000). When p53 is phosphorylated it cannot be degraded by p53 inhibitor HDM2 (MDM2 in mice), 
and therefore the half-life of the protein is increased. During replicative senescence, shortened 
telomeric overhangs, or telomere uncapping is recognised as a DNA single-strand break activating the 
ATM/Chk2 pathway; in OIS, an initial burst of hyper-replication results in a number of stalled 
replication forks recognised as double strand breaks by ATR/Chk1 (d'Adda di Fagagna et al., 2003; Di 
Micco et al., 2006). P53 is also activated when p14ARF (p19Arf in mice) binds and inhibits HDM2. ARF 
is expressed in response to aberrant oncogenic activation and as well as playing a critical role in the 
establishment of senescence in murine cells, its overexpression in human fibroblasts also induces 
senescence in a p53 dependent manner  (Wei et al., 2001; Zindy et al., 1998). 
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interaction with cyclins causing a cell cycle arrest (Figure 1.4) (Alcorta et al., 1996; Serrano et al., 
1993).  
 
1.1.5. Epigenetic regulation of senescence 
Establishment of the irreversible senescent state requires alterations in gene expression and stable 
changes to chromatin structure, suggesting a role for epigenetic regulators (Rai and Adams, 2012).  
Chromatin is the template for epigenetic remodelling and facilitates processes such as transcription, 
DDR, DNA synthesis and mitosis amongst others. Both nucleosomes and DNA can be modified by 
methylation, acetylation and ubiquitination, and this allows various cellular processes to occur 
(Kouzarides, 2007). 
 
1.1.5.1. Epigenetic regulation of the INK4b-ARF-INK4a locus 
When the cell undergoes particular stresses, epigenetic remodelling occurs around the INK4b-ARF-
INK4a locus to activate gene transcription, a key event in the establishment of senescence (Gil and 
Peters, 2006; Serrano et al., 1997). Gene expression at the INK4b-ARF-INK4a locus is tightly 
regulated by a number of different transcription factors.  This includes v-ets erythroblastosis virus E26 
oncogene homologue 2 (ETS2), which positively regulates p16INK4a expression and inhibitor of DNA-
binding 1 (ID1), which represses p16INK4a expression (Cummings et al., 2008; Ohtani et al., 2001; 
Swarbrick et al., 2008).  
 
The ability of transcription factors to bind to the locus during senescence is regulated by additional 
levels of epigenetic control namely the presence or absence of polycomb complexes (Bracken et al., 
2007). In young, unstressed human and mouse cells the INK4a-ARF locus is repressed by Polycomb 
group (PcG) binding and H3 trimethylation at lysine 27 (H3K27me3) (Bracken et al., 2007). Two core 
polycomb complexes exist, Polycomb repressive complex 2 (PRC2) establishes repressive H3K27me3 
marks whereas PRC1 recognises, binds and maintains these repressive marks via histone H2A 
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monoubiquitination at lysine 119 (H2AK119Ub) (Cao et al., 2002; Czermin et al., 2002; Muller et al., 
2002). A number of PcG proteins are thought to have oncogenic properties explained in part by their 
role in repressing p16INK4a expression. Overexpression of PcG proteins, such as BMI1, CBX7 and 
CBX8 delays senescence (Dietrich et al., 2007; Gil et al., 2004; Jacobs et al., 1999; Scott et al., 2007). 
 
During senescence, repressive PcG complexes must be evicted from the INK4b-ARF-INK4a locus for 
gene transcription to occur. This is conducted in part by the removal and replacement of PcG proteins 
with antagonising trithorax (Trx) complexes (Mills, 2010). Trx protein MLL1 is recruited to the INK4b-
ARF-INK4a locus during OIS and catalyses the methylation of Lysine 4 on H3 (H3K4me3), a mark of 
transcriptional activation (Kotake et al., 2009). The SWI/SNF complex of nucleosome remodellers also 
belongs to the Trx family. One of the core components of SWI/SNF, SNF5 mediates polycomb eviction 
from the INK4b-ARF-INK4a locus, thereby restoring p16INK4a expression (Kia et al., 2008). The H3K27 
demethylase JMJD3 can also regulate INK4a/ARF expression during OIS (Agger et al., 2009; 
Barradas et al., 2009). JMJD3 is upregulated during OIS and is recruited to the INK4b-ARF-INK4a 
locus. This leads to demethylation of INK4a/ARF which counteracts PcG mediated H3K27me3 
repression, thereby inducing p16INK4a expression and ARF expression in MEFs (Agger et al., 2009; 
Barradas et al., 2009).  
 
1.1.5.2. Chromosomal architecture during senescence 
Aside from previously mentioned epigenetic characteristics of senescence, such as SAHF formation 
and telomere uncapping, other forms of nuclear and chromosomal remodelling occur that are 
important in senescence establishment (O'Sullivan and Karlseder, 2012). A global reorganisation of 
nucleosome assembly, results in the loss and gains of specific histone variants in the chromatin of 
senescent cells (Dimauro and David, 2009). For example, the linker histone H1 is replaced by non-
histone proteins HMGA1 and HMGA2 on senescent chromatin (Funayama et al., 2006; Narita et al., 
2006). Global changes in nucleosome positioning also occurs during senescence. As human 
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fibroblasts reach replicative senescence the pattern of regularly positioned nucleosomes in young 
cells is gradually shifted into a more irregular pattern (Ishimi et al., 1987).  Human fibroblasts 
undergoing senescence induced by DNA damaging agents have a large decrease in total H3 and H4 
levels, as well as a reduction in H3 biogenesis (O'Sullivan et al., 2010). In ageing budding yeast, H3 
loss is also observed and is due to a decrease in H3 Lysine 56 acetylation (H3K56Ac). Yeast which 
are unable to acetylate H3K56 have a short lifespan and overexpression of H3 or H4 can extend 
cellular lifespan (Feser et al., 2010). 
 
Nuclear architectural proteins are important in organising chromatin domains and transcriptional 
regulation (Cremer and Cremer, 2001). Lamins are structural proteins that bind to core histones and 
are responsible for chromatin positioning within the nucleus. Mutations in the Lamin A gene (LMNA) is 
associated with many disease states, collectively known as laminopathies (Vlcek and Foisner, 2007). 
The Hutchinson–Gilford progeria syndrome (HGPS) is a disease caused by a single mutation in 
LMNA, resulting in a truncated protein product. HGPS patients suffer from premature ageing resulting 
in limited growth, accelerated skin wrinkling and tissue degeneration. Fibroblasts from patients with 
HGPS have deformed nuclear envelope structure, undergo premature senescence and demonstrate a 
global decreases in repressive histone marks H3K9me3 and H3K27me3 (Huang et al., 2008b; 
Shumaker et al., 2006). In cells lacking Lamin A/C, the half-life of the RB1 protein is dramatically 
decreased via proteosomal degradation (Johnson et al., 2004). Recently, Lamin B1 has also been 
linked to senescence, as expression of Lamin B1 decreases during both replicative and OIS (Shimi et 
al., 2011). Silencing of Lamin B1 triggers premature senescence, and the overexpression of this 
protein delays senescence in human fibroblasts (Shimi et al., 2011). 
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production. Although the healthspan of these mice was greatly improved, no extension of lifespan was 
seen with the clearance of senescent cells, suggesting p16INK4a independent pathways also contribute 
to ageing (Baker et al., 2011).  
 
The transcription factor NF-κB, an important mediator of the SASP and oxidative stress and is 
involved in many age-related pathophysiologies such as atherosclerosis, diabetes and cancer (Adler 
et al., 2007; Arkan et al., 2005; Cuaz-Perolin et al., 2008; Tilstra et al., 2012) .  Adler et al., have used 
a mouse model to show that when NF-κB is conditionally inhibited in the skin of aged mice the 
expression profile is more similar to that of younger mice and the skin shows a youthful phenotype 
including an increase in proliferation and thickness, and a decrease in SA-β-Gal activity and p16INK4A 
expression (Adler et al., 2007). A different study examined the effect of NF-κB inhibition in mice with 
XFE progeroid syndrome, a disease of premature ageing resulting from defects in the DDR. In 
progeroid mice, inhibition of the NF-κB pathway decreased signs of DNA damage and senescence, 
and alleviated age-related pathologies associated with XFE progeroid syndrome (Tilstra et al., 2012). 
 
Senescent cells secrete a plethora of factors collectively termed the SASP (Kuilman and Peeper, 
2009). In the last few years a number of studies have highlighted the importance of the SASP in 
interacting with the surrounding microenvironment and immune system in vivo. In a mouse model, 
reactivation of silenced p53 expression in tumourigenic liver cells triggers a senescence response, 
that upregulates the SASP (Xue et al., 2007). SASP upregulation causes clearance of senescent cells 
via activation and recruitment of the innate immune system (Xue et al., 2007). A different study 
showed that NRASG12V expression in liver cells activated senescence and these cells were detected 
by the adaptive immune system, and cleared by the innate immune system (Kang et al., 2011). The 
response was mediated by T-lymphocytes that were specific for senescent cells (Kang et al., 2011). 
Clearance of these senescent cells halted tumourigenesis and mice lacking CD4+ T-lymphocytes 
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were unable to clear the senescent cells and developed hepatocellular carcinoma (HCC) (Kang et al., 
2011). 
 
1.2. Loss-of-function screenings using RNA interference (RNAi) 
To identify novel cancer genes, many studies have turned to high throughput technologies to provide a 
wealth of information with relative ease, and with increasingly reduced costs. Such techniques include 
whole genome sequencing (WGS), comparative genomic hybridisation (CGH) and SNP analysis to 
allow mapping of DNA mutations within tumours. Whole-transcriptome RNA-seq and gene expression 
microarrays have also been used to identify differential expression of genes in cancer samples (Cowin 
et al., 2010; Lizardi et al., 2011). These studies provide valuable insights into identifying potential 
tumour-suppressor genes; however they are unable to distinguish commonly found passenger 
mutations, which do not confer a growth advantage to tumours, from those mutations that are driving 
tumour formation. The use of RNAi to perform loss-of function screens results in the discovery of 
candidates with a causal role in the phenotype being studied (Silva et al., 2008; Zender et al., 2008). 
For these screenings it is pivotal that assay design is optimised to reduce the number of false positive 
and false negative hits obtained (Hu and Luo, 2012). 
 
RNAi was first used in mammalian cells in 2001 to suppress gene expression (Elbashir et al., 2001). 
Short double-stranded RNA (dsRNA) fragments are unwound and the sense strand is incorporated 
into the RISC complex where it binds to complementary mRNAs and causes mRNA transcript 
degradation (Valencia-Sanchez et al., 2006). Two types of RNAi are successfully used for gene 
silencing, small interfering RNA (siRNA) are synthetic anti-sense oligonucleotides that are transfected 
directly into cells, or short hairpin RNA (shRNA) that form a secondary hairpin structure when 
transcribed from DNA (Echeverri and Perrimon, 2006). 
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Both strategies have been used successfully to perform loss-of-function screens (Berns et al., 2004; 
MacKeigan et al., 2005; Meacham et al., 2009). Synthetic siRNAs are easy to produce and in general 
are very efficient at silencing gene expression. However siRNA libraries are relatively expensive and 
transfection of these oligonucleotides only produces a transient knockdown, which is unsuitable for 
long-term assays. SiRNAs are largely used for single-well assays coupled to high-content analysis 
(HCA) using for example an automated microscope. These assays generally screen for complex 
phenotypes such as cell morphology, or protein phosphorylation (Neumann et al., 2006; Pepperkok 
and Ellenberg, 2006). In screenings where long-term gene silencing is required or cells are difficult to 
transfect, viral vectors are used to stably integrate and express shRNAs within cells (Brummelkamp et 
al., 2002b). Vector-based shRNA libraries are less expensive then siRNA libraries and may be used 
indefinitely, however vectors must first be cloned and prepared for transfection, which may be labour 
intensive depending on the size and complexity of library pools. Vector-based shRNAs are the 
silencing method of choice for many in vivo screens that require stable shRNA expression (Bric et al., 
2009; Luo et al., 2009; Wuestefeld et al., 2013).  
 
At present a number of shRNA libraries are available both commercially and through specific 
laboratories. These include libraries from the Netherlands Cancer Institute (NKI), the Hannon-Elledge 
lab and from System Biosciences. These libraries vary in the number of shRNAs contained, the 
genome coverage, the shRNA design and the expression system used (Hu and Luo, 2012). The NKI 
library uses an RNA Pol III expression system to express hairpins with a 19-base double-strand (ds) 
stem and a 9-base loop (Bernards et al., 2006). The Hannon-Elledge libraries are designed based on 
second-generation shRNA libraries that have been developed using an increased knowledge of RNAi. 
Improvements include silencing triggers that are similar to natural microRNA (miR) and an RNA Pol II 
promoter, as Pol II promoters transcribe endogenous primary miR transcripts (Bernards et al., 2006; 
Silva et al., 2005). The hairpins have a 22-base ds stem and a 19-base miR30 loop. Hannon-Elledge 
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libraries have been cloned into multiple vectors each with particular advantages; these miR30 based 
shRNA libraries are therefore well suited for pooled shRNA screenings. 
 
1.2.1. Systems for pooled shRNA screenings 
Pooled shRNA library screenings have become particularly popular as a relatively inexpensive method 
to screen large gene sets without the need for high throughput automation. The most common assays 
conducted using pooled shRNA libraries are those involving the positive selection of shRNAs 
conferring a cell’s enrichment within a population when a particular selection pressure is applied. As 
shRNA screenings can be extended for long periods of time it allows even shRNAs with a modest 
phenotypic effect on cells to be selectively enriched during the process.  
 
Different assays have been adapted for these types of screens. Viability assays select for shRNAs 
which give cells a proliferative advantage to grow under selective pressure (Figure 1.6). In reporter 
screens, a fluorescent marker can be used to identify shRNAs which affect the expression of 
constructs. These cells can then be selected from a pool by FACS analysis. Strategies have been 
adapted to screen for changes in cell morphology, ability to form colonies in soft agar or cells with 
invasive properties characteristic of epithelial-to-mesenchymal transition (Figure 1.6) (Smolen et al., 
2010; Westbrook et al., 2005). 
 
Viral vectors used to infect cells most commonly exist in two types retroviral and lentiviral. Both types 
of virus efficiently integrate DNA into the cell, however only lentiviral vectors can infect non-dividing 
cells, and therefore are better suited for screenings using post-mitotic cells or cells that divide very 
slowly. Hannon-Elledge miR30-shRNA libraries are available as both types; the pSM2 and pSMP 
based libraries produce retrovirus, whereas the pGIPZ and pTRIPZ libraries produce lentivirus (Hu 
and Luo, 2012).  
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even distribution of hairpins from the library. The second time point is the experimental time-point and 
is taken at the end of the assay; hairpins causing a bypass in senescence should be enriched in this 
sample. ShRNAs are amplified similar to previous techniques and samples from different time points 
are labelled with different fluorescent dyes (Figure 1.8). Labelled shRNA sequences are then mixed 
together to competitively hybridise to custom made microarrays containing probes that are specific to 
shRNAs within the library (Schlabach et al., 2008). One advantage of customised microarrays is that 
they allow detection of positive and negative shRNA selection; however barcoded microarrays are 
amenable to non-specific cross-probe hybridisation and also variable hybridisation due to the different 
GC-content of hairpins in the library. 
 
As the cost of next-generation sequencing (NGS) technology has decreased, it has become the 
method of choice for shRNA screening readout, particularly using illumina Solexa technology (Sims et 
al., 2011). The shRNA inserts are PCR amplified using primers that incorporate adaptors at the 
extreme 5’ and 3’ ends to allow hybridisation to a flow cell (Figure 1.8). At this stage it is also possible 
to “tag” each sample with an index or a barcode, which usually consists of a unique 3-5 nt sequence 
within the primer (Meyer and Kircher, 2010). The barcode sequence allows multiple samples to be run 
on a single flow cell and greatly reduces the cost of sequencing. Once sequenced the indexes can be 
deconvoluted to assign the reads to each specific sample. After the shRNAs have been amplified and 
have incorporated adaptors and barcodes, solid support bridge amplification is used to create 
thousands of amplicons of each hybridised shRNA molecule, generating millions of clusters per flow 
cell. The clustered template DNA is sequenced using a sequencing-by-synthesis technique utilising 
reversible terminators and removable fluorophores (Figure 1.8) (Shendure and Ji, 2008).  
 
To assess the feasibility of any screening, it is important to set up assay conditions such that a 
positive control shRNA is able to produce a good signal-to-noise ratio when diluted in a pool of 
shRNAs (Birmingham et al., 2009). This will determine the optimal size of the shRNA pools and 
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optimise other conditions. Background clonal variation is particularly important when a population of 
cells do not act homogenously during a time period, for example due to selective mutations incurred 
before or during the screen. These selective mutations or traits may increase the number of false 
positives detected in the screen, and therefore the timing of the assay must be set to prevent selection 
of these clones.  
 
Another factor to consider in shRNA screenings are off-target effects caused by shRNAs cross-
reacting and silencing genes of near sequence similarity to the intended target (Jackson et al., 2006). 
Off-target effects will increase the number of false-positive hits, however identifying multiple, 
independent hairpins targeting the same gene in a screen will increase the confidence that the 
candidate shRNA is a true positive (Jackson and Linsley, 2010). Libraries comprised of many shRNAs 
targeting each gene will decrease the number of false negative hits due to ineffective gene silencing of 
some shRNAs. Both factors may be overcome by analysing common gene set or pathway enrichment 
within the candidate hits, however this approach is only feasible when conducting large genome-wide 
shRNA screens. Recent work has begun on the production of validated shRNA libraries, containing 
shRNAs able to deliver potent and specific gene silencing (Fellmann et al., 2011). These optimised 
libraries may contain less shRNAs yet result in fewer false positive and false negative hits arising from 
non-specific or weak gene silencing. 
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may be tested using a different but related phenotypic readout to exclude the possibility that artefacts 
developed during the primary screen; for example if the primary screen identified regulators of 
replicative senescence, the candidates can be tested in an OIS system. The possibility of these 
concerns occurring is greatly reduced by sequencing biological replicates of screenings, which will 
decrease the number of false positives detected. 
 
1.3. The SWI/SNF complex in senescence and cancer 
1.3.1. The SWI/SNF complex of chromatin remodellers 
In eukaryotic cells, DNA associates with highly conserved proteins known as histones, to form the 
basic unit of chromatin, a nucleosome. Each nucleosome consists of 146 base pairs (bp) of DNA 
wrapped around an octamer of histones H2A, H2B, H3 and H4, with adjacent nucleosomes being 
connected by DNA and linker histone H1 (Luger et al., 1997; Richmond and Davey, 2003). The 
abundance of linker histone H1 determines the compaction of DNA such that DNA containing high 
levels of H1, known as heterochromatin, appears condensed and is relatively inaccessible to 
transcription machinery and other regulatory factors. In contrast, euchromatin has low levels of H1 and 
the DNA in these regions is loosely arranged and highly transcribed (Dillon and Festenstein, 2002). 
 
Dynamic chromatin states are regulated by macromolecular complexes such as nucleosome 
remodellers. These complexes function in two main ways; by using energy from ATP hydrolysis to 
destabilise DNA-histone interactions, or by covalently modifying histone tails. Both processes result in 
the mobilisation or eviction of nucleosomes regulating access to DNA. Chromatin-remodelling 
enzymes are essential for controlling nuclear organisation in multiple cellular processes, including 
gene expression, DNA replication, DNA repair, development and differentiation. Specifically, the 
SWItching defective/Sucrose Non-Fermenting (SWI/SNF) family have evolved multiple subunits with 
various domains to meet the challenges of gene regulation in higher eukaryotes. 
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1.3.1.1. A multi-subunit complex 
Components of the SWI/SNF complex were first discovered in two screenings identifying genes with 
functions in transcriptional regulation in Saccharomyces cerevisiae (Winston and Carlson, 1992). One 
of the screens identified mutations in genes involved in mating-type switching in yeast. These mutants 
were unable to express haem oxygenase (HO) an endonuclease required for the switching process 
and were termed SWI (SWItching defective) (Neigeborn and Carlson, 1984; Stern et al., 1984). The 
second screen discovered SNF (Sucrose Non-Fermenting) mutants, which could not grow on sucrose 
because they were unable to express the sucrose hydrolysing enzyme β-fructofuranosidase (SUC2) 
(Carlson et al., 1981). Mutations in SWI or SNF genes gave rise to pleiotropic defects (Carlson et al., 
1981; Stern et al., 1984) suggesting these genes are involved in global transcription regulation in 
yeast (Guarente, 1987; Nasmyth et al., 1987; Neigeborn and Carlson, 1984). 
 
By the early 1990s numerous reports had found that Saccharomyces cerevisiae genes identified from 
SWI and SNF screenings belonged to the same multi-subunit complex.  In addition some of the genes 
identified in both screenings were in fact identical and were subsequently termed SWI/SNF genes 
(Cairns et al., 1994; Peterson, 1996; Wolffe, 1994). This complex was required for transcriptional 
enhancement by assisting gene specific regulatory proteins (Laurent et al., 1991; Peterson et al., 
1994; Peterson and Herskowitz, 1992). Because SWI/SNF genes could alter transcription profiles, 
these genes were thought to be involved in chromatin regulation. Mutations in SWI/SNF genes were 
suppressed by deletion of either H2A or H2B genes (hta1, htb1). Furthermore, nuclease sensitivity 
assays detected changes in chromatin structure around the SUC2 promoter, suggesting that the 
SWI/SNF complex functions by antagonising nucleosome-mediated repression (Hirschhorn et al., 
1992). Additional studies found that this nucleosome remodelling was ATP-dependent (Cote et al., 
1994; Kwon et al., 1994) and soon after, homologous ATPase complexes were identified in other 
organisms (Khavari et al., 1993; Tamkun et al., 1992; Wang et al., 1996a). 
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All ATP-dependent chromatin remodellers exist in large multi-subunit complexes (Vignali et al., 2000). 
The SWI/SNF complex is highly conserved in eukaryotes and has been purified from a number of 
organisms including Arabidopsis, Saccharomyces cerevisiae, Drosophila, Xenopus, mice and humans 
(Muchardt and Yaniv, 1999). Mammalian SWI/SNF is thought to be the most complex and diverse 
owing to its higher molecular mass (>2 MDa) and the fact that it exists in multiple forms (Smith et al., 
2003; Wang et al., 1996a). 
Essential to SWI/SNF function is the DNA-dependent ATPase activity. In mammalian complexes this 
activity is executed by one of two mutually exclusive catalytic subunits BRM (Brahma) or BRG1 
(Brahma-Related Gene 1), which share 74% amino acid identity in humans (Khavari et al., 1993). A 
number of subunits bind to either ATPase, and these non-ATPase subunits are known as BRG1/BRM-
associated factors (BAFs) which are identified by their molecular size, for example BAF155 has a 
molecular mass of 155 kDa. Alternatively, SWI/SNF components are sometimes referred to using their 
official HUGO gene nomenclature as SWI/SNF-related, matrix-associated, actin-dependent regulator 
of chromatin (SMARCs) these two classification systems are used interchangeably in the literature 
(Hargreaves and Crabtree, 2011; Ring et al., 1998). 
 
Kingston and co-workers were the first to describe the highly conserved ‘core’ SWI/SNF subunits 
SNF5 (BAF47), BAF155 and BAF170 (Phelan et al., 1999). These proteins together with either BRG1 
or BRM were able to remodel nucleosomes at a level comparable to the entire complex in vitro 
(Phelan et al., 1999). BAF155 and BAF170 are highly homologous (67% identical amino acid 
sequence) scaffolding proteins and can be present in the complex as homodimers or heterodimers 
(Chen and Archer, 2005; Ho et al., 2009b). Yeast SNF5 does not possess any DNA binding activity 
and has not been observed to bind to any specific DNA sequence or motif (Laurent et al., 1990), 
however SNF5 is thought to enhance the DNA binding activity of the whole complex (Hirschhorn et al., 
1992; Peterson et al., 1994).  
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In vivo chromatin remodelling by SWI/SNF requires further ‘accessory’ subunits (Sudarsanam et al., 
2000; Winston and Carlson, 1992). These subunits stabilise the complex and confer target specificity 
by interacting with other proteins in response to certain stimuli or developmental cues (Szerlong et al., 
2008; Zhao et al., 1998). Purification of SWI/SNF complexes from various cells lines demonstrated 
that these complexes were highly heterogeneous in composition (Wang et al., 1996a). Two main types 
of complexes were purified termed the BAF complex and the Polybromo BAF (PBAF) complex (Figure 
1.9) (Nie et al., 2000; Wang et al., 1996a). BAF complexes contained either BRG1 or BRM and were 
associated with one of two AT-Rich Interactive Domain (ARID) containing proteins BAF250A 
(ARID1A) or BAF250B (ARID1B) (Wang et al., 2004). PBAF complexes only contained BRG1. These 
complexes also excluded ARID1A/ARID1B however contained a different ARID-subunit, BAF200 
(ARID2), as well as a protein with multiple bromodomains, BAF180 (Polybromo-1; PBRM1) giving the 
name of the complex (Reisman et al., 2009; Xue et al., 2000; Yan et al., 2005). 
 
1.3.1.2. ATP-dependent nucleosome remodelling 
SWI/SNF are important regulators of gene expression and various gene profiling studies have shown 
that mutations in core SWI/SNF components result in changes in gene expression in 1% of human 
genes, 1-2% of Drosophila genes and 5-7% of all yeast genes (Monahan et al., 2008; Ondrusova et 
al., 2013; Zraly et al., 2006). Nucleosome remodelling is the first and most well studied function of 
SWI/SNF, however numerous other functions exist largely through interactions with DNA binding 
proteins and signalling molecules. 
 
Nucleosome positioning varies across the genome, depending on underlying DNA sequences, DNA 
methylation, nuclear architecture, and promoter/enhancer regions. ATP-dependent chromatin 
remodelling enzymes are required to mobilise nucleosomes and allow DNA-binding proteins access to 
chromatin (Clapier and Cairns, 2009). Four families of ATP-dependent chromatin-remodellers exist; 
SWI/SNF, Imitation SWI (ISWI), NUcleosome Remodelling and Deacetylation/Chromatin Helicase 
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DNA binding (NuRD/CHD), and INOsitol requiring 80 (INO80) (Wu et al., 2009). These families are 
categorised depending on which catalytic subunit is utilised as well as unique associated non-catalytic 
subunits (Clapier and Cairns, 2009). Bromodomains present in BRG1/BRM are unique to SWI/SNF 
catalytic subunits. Furthermore, SWI/SNF does not require extranucleosomal DNA to remodel 
nucleosomes, which distinguishes these complexes from the other nucleosome remodellers, ISWI, 
NuRD/CHD and INO80 which all depend on linker DNA for ATPase activity (Gangaraju and 
Bartholomew, 2007; Kassabov et al., 2003; Udugama et al., 2011; Whitehouse et al., 1999)  
 
The SWI/SNF family remodel nucleosomes via two main mechanisms. The first mechanism involves 
disrupting DNA-histone contacts resulting in nucleosome sliding (cis-displacement) and DNA 
translocation. Alternatively histones can be disassociated with DNA altogether (trans-displacement), 
resulting in nucleosome transfer to a different DNA molecule (Figure 1.9) (Lorch et al., 1999; Owen-
Hughes et al., 1996; Whitehouse et al., 1999). 
 
Nucleosome sliding is achieved in a step-wise process known as the ‘loop-recapture’ model. SWI/SNF 
binds to either nucleosomes or DNA and histone-DNA contacts are disrupted using energy from ATP 
hydrolysis (Aoyagi et al., 2002). Loosening of nucleosome-DNA interactions allows DNA to form a loop 
structure that translocates around the nucleosome in a wave, exposing DNA that was previously 
bound to histones (Saha et al., 2002).  
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1.3.1.3. Regulation of transcription 
ATP-independent SWI/SNF function is attributed to the presence of specialised domains within the 
complex which bind to transcription factors, histone marks and DNA modifying enzymes to regulate 
gene expression. Although SWI/SNF was initially associated with gene activation, numerous findings 
have reported that SWI/SNF complexes also repress transcription (Dunaief et al., 1994; Stankunas et 
al., 2008; Zhan et al., 2011). Various SWI/SNF subunits have been shown to bind to either histone 
deacetylases (HDACs) or histone acetyl-transferases (HATs) to regulate histone acetylation at target 
sites (Drost et al., 2010; Zhang et al., 2000; Zhang et al., 2002). Furthermore core SWI/SNF proteins 
were found to interact with the transcriptional repressor REST and were identified as part of the 
coREST complex (Battaglioli et al., 2002). 
 
1.3.1.4. Specialised domains and exchangeable isoforms  
In 1996 Crabtree and colleagues isolated SWI/SNF complexes from multiple cell lines using an 
antibody specific to the homologous region of BRG1 and BRM. They discovered many distinct 
complexes existed and suggested that SWI/SNF is assembled in a combinatorial fashion, beginning 
with the choice of either BRG1 or BRM as a catalytic subunit (Wang et al., 1996a). Over 10 proteins 
exist in a single SWI/SNF complex and many subunits are encoded by different isoforms within the 
same gene family. These isoforms are mutually exclusive such that only one family member will be 
present in each complex, generating a diverse collection of possible SWI/SNF combinations, each 
having a particular specificity or function.  
 
Further work from the same group and others identified SWI/SNF complexes that are specific for 
particular cell lineages. EsBAF is a SWI/SNF complex exclusively found in ES cells that contains 
BRG1, BAF155 and BAF60a and excludes BRM, BAF170 and BAF60c (Ho et al., 2009b; Kidder et al., 
2009). EsBAF is required to maintain pluripotency via interactions with OCT4. Genome-wide mapping 
of BRG1 in ES cells revealed sites that overlap with OCT4, SOX2 and NANOG occupancy (Ho et al., 
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2009a). Intriguingly BRG1 binding correlated with the repressive histone mark H3K27me3, and 
expression profiling following BRG1 depletion in ES cells suggests that BRG1 has a mainly repressive 
function (Rada-Iglesias et al., 2011) 
 
Differentiation of ES cells into different cell lineages requires intermediary cellular states and gene 
expression changes. These transitions are also regulated by different SWI/SNF complexes. For 
example, neural progenitors and post-mitotic neurons each contain combinations of SWI/SNF 
complexes that are specific to either cell type (npBAF and nBAF respectively) (Lessard et al., 2007; 
Wu et al., 2007; Yoo et al., 2009). In neural progenitors, npBAF is characterised by the inclusion of 
BAF53a and BAF45a and depletion of these subunits limits self-renewal (Lessard et al., 2007). Upon 
terminal differentiation BAF45a and BAF53a are substituted by BAF53b and BAF45b and progenitor 
cells form post-mitotic neurons (Lessard et al., 2007; Wu et al., 2007). In recent years further 
examples of lineage-specific BAF complexes have been identified including cardiocytes and myocytes 
that preferentially assemble SWI/SNF complexes containing BAF60c and BAF45c both of which are 
highly expressed in these tissues (Lei et al., 2012; Lickert et al., 2004; Puri and Mercola, 2012; Willis 
et al., 2012). Thus combinatorial assembly of SWI/SNF has an important role in cell fate 
determination, and lineage commitment.  
 
1.3.2. Role of the SWI/SNF complex in senescence and cancer 
Aberrant epigenetic regulation is a common feature of cancer cells (Jones and Baylin, 2002). DNA 
methylation profiling of human tumours has shown that a high frequency of tumour samples contain 
hypermethylation at CpG island promoters of important senescence regulators such as CDKN2A 
(Gonzalez-Zulueta et al., 1995; Herman et al., 1995; Merlo et al., 1995), BRCA1 (Esteller et al., 2000), 
VHL (Herman et al., 1994) and RB1 (Sakai et al., 1991). The high frequency of deletions to the Trx 
group of proteins (Decristofaro et al., 2001) and overexpression of PcG proteins (Kleer et al., 2003) in 
cancer supports the notion that different changes in the epigenetic machinery could be important for 
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19.6% of all cancer samples from exon sequencing studies have mutations in at least one SWI/SNF 
subunit (Kadoch et al., 2013). Shain and Pollack have also conducted an elaborate study of all the 
whole-exome sequencing data available to explore the extent of SWI/SNF mutations (Shain and 
Pollack, 2013). They conclude that deleterious mutations of all SWI/SNF components (19%) approach 
an overall frequency similar to the highest mutated gene TP53 (26%) supporting the theory that 
SWI/SNF proteins are bone fide “Mut-driver genes” (Vogelstein et al., 2013). 
 
Loss of heterozygosity of SNF5 is found in almost all cases of paediatric rhabdoid sarcomas 
suggesting that SNF5 is a key driver to tumour progression (Biegel et al., 1999; Versteege et al., 
1998). These cancers are highly aggressive however tumour cells appear genomically stable, diploid 
and predominantly devoid of other mutations (McKenna et al., 2008), suggesting that epigenetic 
alterations may substitute for genomic instability in the progression of MRT (Wilson et al., 2010). SNF5 
mutations have also been detected in other tumours at a lower frequency including CML, Hodgkin’s 
lymphoma, paediatric brain tumours (choroid plexus carcinomas) and familial schwannomatosis 
amongst others (Hulsebos et al., 2007; Kohashi et al., 2009; Kreiger et al., 2009; Modena et al., 2005; 
Sevenet et al., 1999; Trobaugh-Lotrario et al., 2009; Yuge et al., 2000) 
 
The catalytic subunit BRG1 is the only SWI/SNF subunit that can act alone to remodel nucleosomes in 
vitro, and it is therefore unsurprising that BRG1 is one of the most commonly mutated subunits across 
all cancers (Table 1.1) (Modena et al., 2005; Shain and Pollack, 2013). Interestingly mutually 
exclusive catalytic subunit BRM has a much lower mutation rate (0.5% compared to 3% for BRG1) 
(Shain and Pollack, 2013). Studies have shown that loss of BRG1 or BRM expression occurs in 
approximately 30% of non-small-cell lung cancer (NSCLC) cell lines, and although a high frequency of 
these cell lines have BRG1 mutations, none show mutations in BRM (Decristofaro et al., 2001; Glaros 
et al., 2007; Reisman et al., 2003; Wong et al., 2000). Instead it was revealed that BRM was 
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epigenetically silenced in cell lines and BRM expression could be restored using histone deacetylase 
(HDAC) inhibitors (Glaros et al., 2007; Yamamichi et al., 2005). 
 
Mutations in accessory SWI/SNF components are also frequent in cancer, particularly in the ‘targeting 
subunits’ ARID1A, ARID1B and PBRM1 (Shain and Pollack, 2013). ARID1A mutations have been 
observed in approximately 50% of ovarian clear cell carcinoma and 30% of endometrioid carcinomas 
(Guan et al., 2011; Jones et al., 2010; Wiegand et al., 2010). A similarly high PBRM1 mutation rate 
(41%) was observed in clear cell renal carcinoma (Varela et al., 2011). ARID1A and ARID1B 
mutations account for 11% of childhood cancer neuroblastomas and these mutation were associated 
with early treatment failure and decreased patient survival (Sausen et al., 2013). Various other studies 
have identified these subunits as driver mutations in breast, colon, pancreatic and hepatocellular 
cancers amongst others (Table 1.1). 
 
Although alterations in SWI/SNF genes are frequently loss-of-function mutations, a subset of cancers 
overexpress certain subunits suggesting that SWI/SNF may have an oncogenic role in these cancers. 
In particular, primary and metastatic melanoma samples have significantly higher BRG1 expression 
levels than dysplastic naevi (Lin et al., 2010). Furthermore knockdown of BRG1 in melanoma cell lines 
reduces cell proliferation (Lin et al., 2010). A similar expression pattern is seen in prostate cancer, as 
the expression of BRG1 increases in malignant and invasive prostate cancer compared to benign 
lesions, however the opposite was seen for BRM suggesting that elevated levels of BRG1 may be a 
consequence of BRM loss in these tumours (Sun et al., 2007). 
 
In conclusion, mutations in SWI/SNF subunits are predominantly “tumour-driving” events as opposed 
to background passenger mutations. This concept is strengthened by the evidence that inactivating 
mutations in SWI/SNF proteins make up 71% of all SWI/SNF mutations whereas only 41% of 
mutations in all exome sequenced genes are deleterious (Figure 1.11.) (Shain and Pollack, 2013). 
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1.3.2.2. Relationship between the SWI/SNF complex and senescence 
Although the profile of SWI/SNF mutations in cancer has been studied in great depth, mechanisms of 
tumour suppression are not well defined. The SWI/SNF complex has been associated with the 
regulation of numerous signalling pathways in cancer (Figure 1.10.) (Wilson and Roberts, 2011). The 
exact role of SWI/SNF in specific cell types or conditions is difficult to predict because of the diverse 
number of complexes available. However some patterns of SWI/SNF activity are emerging across cell 
types, in particular the overlap between SWI/SNF function and activation of senescence pathways. 
 
1.3.2.2.1. SNF5 
One of the core subunits of the SWI/SNF complex, SNF5 has been shown modulate senescence via 
the activation of p16INK4a, p21CIP1 and p19ARF expression. SNF5 can displace PcG complexes at the 
INK4a/ARF locus (Kia et al., 2008). This displacement of PcG, results in de-repression of the 
INK4a/ARF promoter via loss of the repressive H3K27me3 mark and re-activation of gene expression 
through recruitment of BRG1 and Pol II (McKenna et al., 2008; Wilson et al., 2010). Similarly in mice 
expressing K-RASG12D, SNF5 opposes the action of Polycomb and activates p19ARF expression 
(Young and Jacks, 2010). As a result Snf5 null mice form tumours from an early onset, with a median 
age of 11 weeks (Wilson et al., 2010). These tumours have high levels of PcG protein Enhancer of 
Zeste Homologue 2 (Ezh2), and Ezh2 is essential for tumour formation in these mice; supporting the 
idea that Snf5 represses PcG activity to prevent tumour formation (Wilson et al., 2010; Young and 
Jacks, 2010). 
 
In mouse models for conditional bi-allelic inactivation of Snf5, heterozygous Snf5 mice form tumours 
that are phenotypically similar to human rhabdoid tumors (Isakoff et al., 2005; Tsikitis et al., 2005; 
Zhang et al., 2002). P53 loss in these mice further accelerates tumour formation suggesting that Snf5 
and p53 may co-operate in tumour-suppression (Isakoff et al., 2005). Levels of cyclin D1 are also 
elevated in tumours formed in this mouse model. When heterozygous Snf5 mice were crossed with 
cyclin D1 null mice the number of tumours arising during Snf5 inactivation was significantly decreased 
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compared to parental Snf5 heterozygous mice, suggesting increased cyclin D1 expression is 
important for the tumour promoting mechanisms in Snf5 null mice  (Tsikitis et al., 2005).  
 
Various groups have reported that expression of SNF5 in SNF5-null rhabdoid tumour cell-lines results 
in a growth arrest defined by a flattened cellular morphology and increase in SA-β-Gal activity 
(McKenna et al., 2008; Wilson et al., 2010). One proposed mechanism is that SNF5 binds to p53 and 
BRG1 to activate p21CIP1 transcription (Chai et al., 2005; Lee et al., 2002a). In a similar cell line, 
reintroduction of SNF5 brings HDAC1 to the cyclin D1 promoter and results in transcriptional 
repression of cyclin D1 (Zhang et al., 2002). Thus, SNF5 is able to bind to the promoters of important 
cell cycle proteins and regulate transcription through recruitment of transcriptional activators and 
repressors (Chai et al., 2005; Kuwahara et al., 2010; Lee et al., 2002a; Xu et al., 2010).  
 
1.3.2.2.2. BRG1/BRM 
BRG1 was first associated with senescence when it was found to bind to hypo-phosphorylated RB1 
and induce cell cycle arrest (Dunaief et al., 1994). Soon after, BRM was also shown to interact with 
RB1 and both BRG1 and BRM can also interact with other members of the pocket-protein family p107 
and p130 (Strober et al., 1996; Trouche et al., 1997). BRG1/BRM contain an LXCXE motif which was 
initially thought to bind to the pocket domain, an interaction which is disrupted in the presence of viral 
oncoproteins SV40 T antigen, adenovirus E1 A and HPV16 E7 which bind to the same region of RB1 
(Dunaief et al., 1994). Further investigations showed that mutations in the LXCXE domain of 
BRG1/BRM did not hinder RB1 binding and that neighboring regions were responsible for the 
observed interaction (Strober et al., 1996; Trouche et al., 1997). In the SW13 cell-line, which does not 
express BRG1/BRM, overexpression of either BRG1/BRM induces a senescence like arrest, with cells 
acquiring a flat enlarged morphology and increased SA-β-gal activity (Dunaief et al., 1994; Strober et 
al., 1996). RB1 is necessary for this arrest as it forms a repressive transcriptional complex through the 
recruitment of HDAC1 (Trouche et al., 1997; Zhang et al., 2000). This BRG1/BRM-RB1-HDAC 
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complex represses transcription of E2F target genes such as cyclin E, cyclin A and cdc2 (Trouche et 
al., 1997; Zhang et al., 2000). HDACs also contain the LXCXE motif, which interacts with the RB1 
pocket domain (Siddiqui et al., 2003). A similar transcriptional repressor complex was identified in the 
livers of old mice but not young ones. BRM is induced in old mice initiating the formation of a C/EBPα-
Rb-E2F4-Brm complex (Iakova et al., 2003). This complex represses transcription of E2F regulated 
genes, including c-myc, in quiescent and regenerating livers of old mice (Iakova et al., 2003). Thus the 
BRM-Rb complex present in livers of ageing mice, causes a lack of proliferative response and growth 
arrest in old mice (Iakova et al., 2003). 
 
A study in 2009 identified BRG1 as a binding partner of the important senescence regulator p16INK4a 
(Becker et al., 2009). A yeast two-hybrid screen using human p16INK4a as bait, captured the C-terminal 
region of BRG1. Verification of this interaction was performed by co-immunoprecipitating over-
expressed MYC-tagged p16INK4a and over-expressed FLAG-tagged BRG1 in U2OS osteosarcoma 
cells. Visualisation of these tagged proteins expressed in the SW13 adrenocortical carcinoma cell line 
showed nuclear co-localisation further supporting an interaction (Becker et al., 2009). However no 
similar reports supporting this interaction with endogenous proteins have emerged. Contrary to other 
reports the study also claimed that BRG1 was not required for RB1 mediated senescence, and that 
BRG1 has no role in p16INK4a-mediated cell cycle arrest (Becker et al., 2009; Strobeck et al., 2000). 
 
BRG1/BRM can also regulate the p53/p21CIP1 pathway. BRG1 has been shown to bind to the p21CIP1 
promoter and facilitate its transcriptional activation (Giraud et al., 2004; Guan et al., 2011; Kang et al., 
2004; Tu et al., 2013). BRG1 can activate p21CIP1 expression by binding to Signal Transducer and 
Activator of Transcription 3 transcription factor (STAT3) (Giraud et al., 2004). The STAT3-BRG1 
interaction occurs under specific stimuli, in particular through IL-6 induction (Ni and Bremner, 2007). 
Interestingly, rapid induction of certain IL-6-responsive genes including IFITM3 and IFI16 is dependent 
on BRG1 recruitment to these gene promoters (Ni and Bremner, 2007). 
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BRG1 has been shown to interact with p53 in a number of different cell lines, although the outcome of 
this interaction appears to be cell-type specific. In U2OS and Saos-2 cells BRG1 mediates p53 
transactivation function and suppresses cell proliferation (Lee et al., 2002a). In MCF7 cells BRG1 is 
required to activate transcription of a subset of p53 genes (Xu et al., 2007). Similarly in rat 
mesenchymal stem cells (MSC), ectopic Brg1 expression induces senescence or apoptosis that is 
dependent on the presence of p53 (Napolitano et al., 2007). Intriguingly the same group observed that 
in rat MSC, knockdown of BRG1 also induced cell senescence but not apoptosis. This senescence 
response was coupled to p53 activation measured by an increase in phosphorylated Ser15-p53 and 
acetylated Lys379-p53 (Alessio et al., 2010). Depletion of BRG1 in HeLa, G401 and RK0 cell lines 
also showed that BRG1 silencing stabilises p53, and results in an upregulation of p53 target genes 
(Naidu et al., 2009). In these cell lines BRG1 regulates p53 levels by forming a complex with CREB-
binding protein (CBP) that mediates p53 poly-ubiquitination and degradation (Naidu et al., 2009). 
 
1.3.2.2.3. ARID1A/ARID1B  
ARID1A and ARID1B are mutually exclusive components of the BAF complex. These proteins are the 
largest subunits of the SWI/SNF complex and target the complex to DNA through the ARID domain 
(Kortschak et al., 2000). Initial studies on the role of ARID1A/ARID1B suggested that they have 
antagonistic roles during differentiation (Nagl et al., 2005; Nagl et al., 2007). Recent evidence from 
overexpression studies show that both ARID1A and ARID1B control cell proliferation (Guan et al., 
2011; Inoue et al., 2011). 
 
Mutations in ARID1A occur in a high frequency of ovarian cancers and are mutually exclusive to TP53 
and RAS mutations suggesting functional redundancy (Jones et al., 2010; Wiegand et al., 2010).  
Knockdown of ARID1A in a non-transformed ovarian epithelial cell line enhances the proliferation and 
tumourigenicity of these cells (Guan et al., 2011). Furthermore, re-introduction of ARID1A in cell lines 
or tumours with ARID1A knockdown results in a significant reduction in cell and tumour growth (Guan 
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et al., 2011). Analysis of the mechanism of ARID1A tumour suppression identified ARID1A as a p53 
binding partner (Guan et al., 2011). The p53-ARID1A interaction recruited BRG1 and Pol II to the 
promoters of known p53 target genes such as CDKN1a and SMAD3 and enhanced their 
transcriptional activation (Guan et al., 2011). Activation of p21CIP1 is an important event in ARID1A 
mediated tumour suppression as p21CIP1 knockdown is able to bypass the growth arrest caused by 
ARID1A overexpression in ovarian epithelial cell lines (Guan et al., 2011). 
 
ARID1A and ARID1B are highly mutated in pancreatic cancer suggesting a tumour suppressive 
function (Shain et al., 2012). Depletion of either ARID1A/ARID1B with siRNA, results in an increase in 
proliferation in some pancreatic cancer cell lines (Shain et al., 2012). Gene expression profiling in 
human pancreatic duct epithelial (HPDE) cells shows Polycomb-related gene sets are significantly 
enriched following ARID1A/ARID1B knockdown, supporting the idea that SWI/SNF opposes PcG 
function in tumourigenesis (Shain et al., 2012; Wilson et al., 2010). In contrast, a different study 
showed that ectopic expression of ARID1B into the MiaPaCa2 pancreatic cancer cell line did not affect 
cell growth but affected their ability to grow in soft agar (Khursheed et al., 2013).  
 
In HeLa cells, overexpression of ARID1B reduced cell proliferation and a higher percentage of cells 
were found in the G0/G1 cell cycle phase (Inoue et al., 2011). ARID1B caused an increase in p21CIP1, 
and p53 levels in these cells and depleted c-myc levels (Inoue et al., 2011). ChIP analysis showed 
ARID1B bound to p21CIP1 and c-myc promoters, however association with p53 was not investigated 
(Inoue et al., 2011). Furthermore, ARID1B depletion promotes cell proliferation in human HCC cell 
lines, however the mechanism of increased cell growth is unknown (Fujimoto et al., 2012). 
 
1.3.2.2.4. PBRM1/BRD7 
BAF180 and BRD7 are components of the PBAF complex with an important role in p53 regulation. A 
genome-wide shRNA screening in primary BJ fibroblasts identified BRD7 and BAF180 as regulators of 
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replicative senescence (Burrows et al., 2010). Further investigation showed that depletion of these 
proteins prevented OIS, and reduced levels of p21CIP1 (Burrows et al., 2010; Drost et al., 2010). Over-
expression of BRD7 induced premature senescence, coupled to an upregulation of p21CIP1 levels 
(Burrows et al., 2010; Drost et al., 2010). Two reports have identified the interaction between BRD7 
and p53 as necessary for transcriptional activation of a subset of p53 target genes, including p21CIP1 
(Burrows et al., 2010; Drost et al., 2010). BRD7 forms a complex with PBAF-p300-p53 to acetylate 
target gene promoters and activate gene expression (Drost et al., 2010). ChIP analysis demonstrated 
that BRD7 also binds to non-p53 target gene promoters during OIS, suggesting BRD7 may also 
function independently of p53 (Drost et al., 2010). BRD7 overexpression in naso-pharyngeal 
carcinoma (NPC) causes a G1 cell arrest that is characterised by upregulation of genes involved in the 
RAS/MEK/ERK and RB1/E2F pathways (Peng et al., 2007; Zhou et al., 2004).  
 
1.3.2.2.5. Role of SWI/SNF in SAHF formation  
Senescent cells undergo dramatic changes in chromatin structure and contain SAHFs (Chandra et al., 
2012; Narita et al., 2003a; Zhang et al., 2005). The SWI/SNF complex interacts with multiple SAHF 
components and plays a role in SAHF formation. SAHFs contain HP1 and histone variant macroH2A 
which assist in the formation of heterochromatic structures (Zhang et al., 2005). It has been shown 
that BRG1/BRM catalytic activity is required to recruit HP1 proteins to chromatin in vitro (Lavigne et 
al., 2009). BRG1/BRM facilitate access to the HP1 contact site inside of the nucleosome so that HP1 
can enter and compete with SWI/SNF for binding, preventing further remodelling (Lavigne et al., 
2009). Furthermore the histone chaperone ASF1a, an essential factor in SAHF formation, is a known 
interactor of BRM (Moshkin et al., 2002; Zhang et al., 2005). It has been proposed, but not proven, 
that BRM may be required for the incorporation of macroH2A into SAHFs as BRM activity is necessary 
for the formation of RB1/HP1β foci in senescent melanocytic nevi (Bandyopadhyay et al., 2007).  
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More recently Zhang and colleagues have described a clear link between BRG1 and SAHF formation 
(Tu et al., 2013). In this study it was shown that chromatin-associated BRG1 levels increase during 
OIS, as does the association between BRG1 and RB1 (Tu et al., 2013). Furthermore, knockdown of 
BRG1 during OIS inhibits SAHF formation and overexpression of BRG1 induced senescence and 
increased SAHF formation (Tu et al., 2013). BRG1-induced SAHF formation was dependent on its 
interaction with RB1 (Tu et al., 2013). 
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Chapter 2. Materials and Methods 
 
2.1. Libraries  
2.1.1. HCC deletion library 
An shRNA library targeting the mouse orthologues of genes frequently deleted in human HCC 
(hereafter referred to as HCC library) was obtained from Lars Zender (Zender et al., 2008). The HCC 
library consists of 624 shRNA constructs divided into 13 pools (Figure 3.1). 1.54 μg from each pool 
was mixed to create a HCC library super pool for transfections. 
  
2.1.2. pGIPZ genome-wide library 
Aliquots of the pGIPZ human genome-wide shRNA library were obtained from Lars Zender. 60,000 
shRNA constructs were divided into 60 pools. 1 μL of aliquot from a pool was used to transform one 
vial of One Shot® Stbl3™ Chemically Competent E. coli following manufacturer’s recommendations. 
E. coli were mixed with SOC media to a final volume of 500 μL. After incubating for 1 h at 37°C with 
gentle shaking, 480 μL of the transformation mixture was plated on a 15 cm dish (containing low salt 
LB Agar with 100 μg/mL Ampicillin and 25 μg/mL Zeocin). The remaining transformation mixture was 
diluted 1,000 and 10,000 times and plated on 10 cm dishes to determine the number of individual 
transformants. All dishes were incubated at 37°C overnight. The following day bacterial growth from 
the 15 cm dish was scraped into 300 mL of low salt LB broth containing 100 μg/mL Ampicillin and 25 
μg/mL Zeocin and was grown for 10 h at 30°C (to reduce recombination of viral vectors) with vigorous 
shaking. Plasmid DNA was purified as described below. The number of colonies arising from the 10 
cm dishes were counted and used to calculate the average efficiency of the transformation. Colonies 
arising from the 10 cm dishes were also analysed by PCR to assess if constructs had recombined. 5 
colonies were picked at random and plasmid recombination was assessed by PCR, using primers 
designed to amplify a region spanning the full length of the hairpin between the two LTRs (primer 
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sequences are given in Table A8). PCR products were run on an agarose gel to check the size of the 
amplicon as described below. 
 
2.2. Cell lines and tissue culture methods  
All tissue culture reagents were purchased from Invitrogen (Invitrogen Ltd, Paisley, UK), unless 
otherwise stated. All chemicals were purchased from Sigma (Sigma-Aldrich, Dorset, UK), unless 
otherwise stated. 
 
IMR-90 human foetal lung fibroblasts and HEK293T packaging cells were obtained from the American 
Type Culture Collection (ATCC). HEK293T packaging cells expressing retrovirus structural genes 
(gag-pol and env) were obtained from Takara BIO INC. MEFs were prepared from 13.5-day-old 
embryos of CD1 mice. The head and viscera were removed and the remaining tissue was minced 
using scalpels. A single cell suspension was obtained by trypsinisation (0.25% (v/v)) at 37°C for 15 
min with periodic mincing.  Cells were cultured for 1-2 days until they became confluent and were then 
frozen in foetal bovine serum (FBS; PAA) containing 10% dimethyl sulfoxide (DMSO) (v/v). IMR-90, 
HEK293T and MEFs and were cultured in complete medium (Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic-antimycotic), and grown in humidity 
at 37°C with 5% CO2. Inducible ER:RAS cells were prepared from IMR-90 infected with pLNC-
ER:RAS, a vector expressing the constitutively active form of RAS (RASG12V) fused to the ligand-
binding domain of the oestrogen receptor (ER). Cells are treated 1 day post seeding with 4OHT (100 
nM reconstituted in DMSO) to induce senescence as previously described (Acosta et al., 2008; 
Barradas et al., 2009). 
 
2.3. Retrovirus production and transduction of target cells  
HEK293T cells were seeded the previous day to obtain a confluence of 70-80% for the day of 
transfection. For each transfection, 1 mL of DMEM was mixed with 20 μg of expression plasmid, 2.5 
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μg of VSV-g and 75 μL of linear 25 kDa linear polyethylenimine (PEI; 1 mg/mL (w/v), Polysciences). 
The transfection mixture was incubated at room temperature for approximately 30 min and added 
drop-wise to each plate of HEK293T. Transfection efficiency was monitored the next day by the 
presence of GFP (green fluorescent protein) or mCherry fluorescent protein expressed from a reporter 
plasmid (for a list of plasmids see Table A5). The day after transfection, the media of the transduced 
packaging cells was replaced (6 mL/plate).  On the same day, target cells (MEFs or IMR-90) were 
plated at a density of 106 cells per 10 cm plate.  
 
After 48 h viral supernatants produced by packaging cells were collected and filtered through 0.45 μm 
pore-sized acetate filters (Anachem) and supplemented with 4 μg/mL of polybrene. The culture media 
of the target cells was then replaced by the filtered virus-containing supernatant. Infection took place 
2-3 times to maximize the transduction efficiency and a period of 3-5 h was left between each round 
for virus production. The media of the infected cells was replaced with fresh complete medium post 
infection.  
 
The percentage of infected cells was determined by flow cytometry using reporter plasmids expressing 
GFP or mCherry and using uninfected cells as a negative control. Two days after infection, cells were 
split and grown for 5-7 days in the presence of puromycin (0.5 μg/mL) or for 1-2 weeks in 200 μg/mL 
G418 in order to select for infected cells. 
 
2.4. Lentivirus production and transduction of target cells 
HEK293T cells were seeded the previous day to obtain a confluency of 70-80% for the day of 
transfection. For each transfection, 1 mL of DMEM containing 10 μg of expression plasmid, 10 μg of 
psPAX2 helper plasmid, 2 μg of VSV-g plasmid and 75 μL of PEI (1 mg/mL) was used (unless 
otherwise stated) and added to cells as before. The following day media of the transduced packaging 
cells was replaced (6 mL/plate).  In parallel target IMR-90 cells were plated at a density of 106 cells 
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per 10 cm plate for each infection. After 48 h, viral supernatants were collected from packaging cells 
and filtered through 0.45 μm pore-sized acetate filters. 1.5 mL of supernatant was mixed with 4.5 mL 
of complete media (to obtain a viral supernatant dilution of 4). Polybrene was added to a final 
concentration of 4 μg/mL. The culture media of the target cells was replaced with diluted viral 
supernatant for 5 h. The media of infected cells was replaced with fresh complete medium post 
infection.  
 
2.5. Generation of custom Solexa libraries 
2.5.1. Genomic DNA isolation 
Cells infected with the library were collected by trypsinisation and centrifugation. Genomic DNA was 
extracted from pellets using DNeasy Blood and Tissue Kit (QIAGEN) following manufacturer’s 
instructions. The final elution volume was 50 μL in sterile distilled water. The DNA concentration was 
determined by measuring the absorbance at 260 nm (A260) using a NanoDrop® ND-1000 UV-Vis 
spectrophotometer. 
 
2.5.2. Solexa PCR 
Duplicate PCR reactions were performed for each sample. 1 μg of extracted DNA was added to 45 μL 
of PCR SuperMix High Fidelity and 1 μL of each forward and reverse primers (10 μM). Primers are 
ligated to Solexa adaptors and also contain a 3 nt barcode for assigning sample specificity (Figure 
2.2). Blank samples containing no genomic DNA were prepared in parallel for each primer set to 
assess the presence of contaminants. PCR conditions are as follows: 95°C 10 min, 95°C 30 s, 52°C 
45 s, 72°C 60 s. Repeat steps 2-4 34 times. Final incubation 72°C for 10 min. For a list of Solexa PCR 
primers see Table A7. 
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2.5.3. DNA purification and quantification 
Solexa PCR products were analysed on an agarose gel. DNA loading buffer (Orange G 0.2% (w/v) in 
3% glycerol (v/v)) was added to the samples, which were then resolved on a 2.5% agarose (w/v) gel 
with 0.5 μg/mL ethidium bromide. A one lane gap was left between samples to prevent cross 
contamination. Samples were separated at 100 V in TAE buffer (40 mM Tris and 1 mM EDTA (pH 8.0) 
in 0.1% HAc (v/v)). For DNA visualisation, the gel was exposed to UV using the Bio-Rad Gel Doc™ 
2000 system. Image analysis was carried out using the Quantity One® (version 4.4.1) software (Bio-
Rad). The size of the DNA fragments was estimated by using a 100 bp DNA ladder (New England 
Biolabs) as a reference. PCR products should be in the range of 115 bp (barcoded) to 117 bp (non-
barcoded). The band corresponding to each PCR product was extracted from agarose gels using a 
clean scalpel. QIAquick Gel Extraction kit (QIAGEN) was used to recover PCR products following 
manufacturer’s instructions. DNA was eluted in 20 μL of sterile distilled water.  
 
Gel extracted DNA was quantified using Qubit® dsDNA HS Assay kit and measured on the Qubit® 2.0 
Fluorometer following manufacturer’s guidelines. The individual barcoded PCR-products were then 
pooled in equal quantities to form a Solexa sequencing library.  
 
2.6. Next-generation sequencing 
2.6.1. Solexa library quality control 
Quality control of the Solexa library involved precise assessment of the Solexa PCR product size and 
purity using Agilent High Sensitivity DNA Kit and Agilent 2100 Bioanalyser. An aliquot of library was 
diluted to 100-300 pg/μL and profiles shown in Figure 2.1 were deemed of sufficient purity to run. The 
amount of amplifiable DNA amenable for clustering on Solexa flowcells was determined after qPCR 
using Solexa flow cell primers. QPCRs were performed by CSC genomic lab staff.  
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 Figure 2.1. Bioanalyser profile of acceptable custom Solexa library for NGS. Diluted Solexa libraries were 
run on the Agilent 2100 Bioanalyser using the Agilent High Sensitivity DNA Kit. A profile deemed of suitable purity 
to use for HTS should contain a single dominant peak in the range of 117-125 bp. 
 
2.6.2. High-throughput sequencing 
6 pM of the Solexa library was used to create clusters by bridge amplification on a single lane of a 
Solexa flowcell and sequenced on the Genome Analyser IIx (GAIIx) at either the Helmholtz Centre for 
Infection Research (HZI) or the CSC Genomics Laboratory, Clinical Sciences Centre (CSC). The 
miR30 sequencing primer used was HPLC purified and reconstituted in sterile distilled water (for a list 
of sequencing primers see Table A8). 
 
2.6.3. Bioinformatics 
FASTA files produced from the sequencing runs were processed by Adam Geiss using RTA version 
1.8.70.0, with default filter and quality settings against a PhiX control lane. Sequences were first de-
multiplexed with CASAVA 1.7 to allow ‘binning’ of samples by barcode bases 35-37. The reverse 
complement of each read was aligned to the custom HCC or pGIPZ libraries using the ELAND 
extended implementation of CASAVA 1.7. Bases 3-19 of each read were used, reporting exact 
matches only (Figure 2.2). Hairpin sequence proportions were calculated for samples and ranked 
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using a Fisher’s combined p-value by Tom Carroll using R (v2.13.0). The Fisher’s combined test 
allows p-values across independent data sets to be combined (Fisher, 1925).  
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2.7. Growth assays  
2.7.1. Growth curves and colony formation assays  
For growth curves 5×105 (IMR-90) or 106 (MEFs) cells were seeded per 10 cm plates in duplicate. Cell 
number was estimated every 5-7 days (IMR-90) or 3-4 days (MEFs) until the empty vector (control) 
reached senescence. Cells were trypsinised and resuspended in 3-12 mL of complete media. 50 μL of 
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resuspended cells was diluted in 150 μL of Guava® ViaCount® reagent (Millipore) and applied to the 
Guava microcapillary flow cytometry system (Millipore). Debris and non-viable cells were gated to be 
excluded from the final cell count and cell numbers were quantified using Guava® ViaCount® assay 
software (Millipore). 
 
Short-term growth curves were conducted by plating 500-1000 cells per 96-well dish in triplicate. Cells 
were washed with PBS once and fixed for 20 min with 4% paraformaldehyde (PFA, (w/v)) every 2 
days. Cells were stained with 1 μM 4',6-diamidino-2-phenylindole (DAPI) for 10 min and fluorescent 
images of stained cells were acquired using the IN Cell Analyzer 1000 automated high-throughput 
microscope (GE Healthcare). Image processing and quantification of nuclei was performed using the 
IN Cell Investigator (v1.7) software (GE Healthcare) (see High Content Analysis). Growth curves were 
normalised relative to the average number of cells in the ‘day 0’ sample fixed one day post plating.    
 
For colony formation assays cells were plated at a low density of either 5×104 or 105 in 10 cm plates 
and between 104 - 2x105 per 6-well dish. Cells were washed with PBS and fixed with 0.5% 
glutaraldehyde (w/v) in PBS for 10 min. Cells were washed twice with distilled water and all plates 
were stained simultaneously with 0.2% crystal violet (w/v). Crystal violet was extracted with 10% 
acetic acid (v/v) and the absorbance at 595 nm (A595) was measured using the Bio-Rad 680XR 
microplate reader. Absorbance values were used to quantify relative cell growth and were plotted 
normalised to cells transduced with an empty vector.  
 
2.7.2. BrdU (5-Bromo-2’-deoxyuridine) incorporation assay   
Cells (1-4x103) were plated in 96-well plates in duplicate and allowed to adhere overnight. The 
following day, cells were incubated with 5-Bromo-2′-deoxyuridine (BrdU, 50 μM) for 16-20 h. After 
incubation, cells were washed with PBS and fixed for 20 min with 4% PFA (w/v). For 
immunofluorescence staining, cells were first permeabilised for 10 min with 0.25% (v/v) Triton X-100 in 
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PBS and incubated for 1 h with blocking solution (0.5% (w/v) BSA, 0.2% (w/v) fish skin gelatine). 
Treatment with DNase I (0.5 U/µL) in presence of 1 mM MgCl2 was performed simultaneously with 
Alexa Fluor® 488 mouse anti-BrdU antibody (1:100, Invitrogen) and incubated for 30 min at room 
temperature. Cells were washed three times with PBS and incubated with 1 µM DAPI for 10 min. 
Plates were examined using the IN Cell Analyzer 1000 automated high-throughput microscope (GE 
Healthcare) with a 10x objective. High Content Analysis (HCA) was used to quantify the proportion of 
BrdU positive nuclei. Image processing was performed using the IN Cell Investigator (v1.7) software 
(GE Healthcare) (see High Content Analysis). 
 
2.7.3. Senescence-associated β-galactosidase (SA-β-gal) assay 
2.7.3.1. Cytochemical staining 
103 - 6x104 cells were plated per 6-well dish and 2-7 days later cells were washed once with PBS and 
fixed with 0.5% glutaraldehyde (w/v) for 5 min. Fixed cells were washed twice with 1 mM MgCl2 in 
PBS (pH 6.0) and then incubated with X-Gal staining solution (1 mg/mL X-Gal (Promega), 5 mM 
K3[Fe(CN)6] and 5 mM K4[Fe(CN)6] in 1 mM MgCl2/PBS (pH 6.0)) for 8–24 h, after which the cells 
were washed with water and stored at 4 °C, in the dark. Bright field (BF) colour images were taken 
using the Olympus CKX41 inverted fluorescence microscope, supplied with a DP20 digital camera. 
The percentage of SA-β-Gal-positive cells was determined by counting at least 150 cells.  
 
 
 
2.7.3.2. Fluorescence visualisation 
SA-β-gal activity was detected as described in Debacq-Chainiaux et al., 2009. 4x103 cells were plated 
per 96-well dish in duplicate wells. 2 days later cells were incubated with fresh complete medium 
containing C12FDG (33 μM) and incubated for 2 h. Following incubation cells were washed twice with 
PBS and were fixed for 20 min with 4% PFA (w/v). Fixative was removed by washing twice with PBS 
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and cells were stained with 1 μM DAPI for 10 min. Fluorescence was visualised using the IN Cell 
Analyzer 1000 automated high-throughput microscope (GE Healthcare). Image processing and 
quantification of nuclei was performed using the IN Cell Investigator (v1.7) software (GE Healthcare) 
(see High Content Analysis). At least 500 cells were counted per replicate. 
 
2.8. Generation of shRNA expressing retroviral vectors  
2.8.1. shRNA constructs 
Retroviral plasmids for knockdown of human and mouse genes were constructed by sub-cloning 
oligonucleotides into pRetroSuper (pRS), as previously described (Brummelkamp et al., 2002a). 
Oligonucleotides were designed using the BIOPREDsi (www.biopredsi.org) or DSIR 
(http://biodev.extra.cea.fr/DSIR/DSIR.html) algorithms to computationally predict shRNA target 
sequences with an optimal knockdown effect. A minimum of three independent shRNA constructs 
were designed and tested for each gene. The forward and reverse strands of the oligonucleotides 
were annealed in shRNA annealing buffer (100 mM NaCl and 50 mM HEPES, pH 7.4). The 
oligonucleotides were then incubated for 4 min at 90 °C, then for 10 min at 70 °C and slowly cooled to 
10 °C or room temperature. The annealed oligos were cloned between the unique BglII and HindIII 
enzyme sites of the pRS vector using T4 DNA ligase (New England Biolabs). One Shot® TOP10 
competent cells were transformed and plated on LB agar plates following manufacturer’s guidelines. 
The presence of positive clones was verified by colony PCR, using primers spanning the full hairpin 
region (for a full list of shRNA target sequences see Table A6). The PCR products were resolved on a 
2.5% agarose (w/v) gel (see Agarose gel electrophoresis). Positive colonies were grown in 300 mL of 
LB medium containing 100 μg/mL Ampicillin for 12–16 h at 37 °C, with vigorous shaking. 
 
2.8.2. Plasmid DNA purification 
Bacterial cell cultures were pelleted by centrifugation at 6000 × g for 15 min at 4 °C. Large-scale 
plasmid DNA preparation was carried out using the HiSpeed® Plasmid Purification kit (QIAGEN) 
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following manufacturer’s guidelines. DNA was eluted with 1 mL sterile distilled water. The 
concentration was determined by measuring the absorbance at 260 nm (A260) in a NanoDrop® ND-
1000 UV-Vis spectrophotometer. The DNA was stored at –20 °C for future applications.  
 
2.8.3. Agarose gel electrophoresis and DNA purification 
Restriction enzyme-digested DNA and PCR products were analysed by their electrophoretic mobility 
on an agarose gel. DNA loading buffer (Orange G 0.2% (w/v) in 3% glycerol (v/v)) was added to the 
samples, which were then resolved on a 1–2.5% agarose (w/v) gel with 0.5 μg/mL ethidium bromide. 
Samples were separated at 100 V for 30–60 min in TAE buffer (40 mM Tris and 1 mM EDTA (pH 8.0) 
in 0.1% HAc (v/v)). DNA bands were visualised as before. 
 
The QIAquick Gel Extraction kit (QIAGEN) was used to extract and purify DNA (70 bp–10 kb) from 
agarose. The DNA fragment was excised from the agarose gel using a clean scalpel and DNA was 
purified following manufacturer’s instructions. DNA was eluted in 30–50 µL sterile distilled water. 
 
2.8.4. DNA sequencing 
For each sequencing reaction 600 ng of plasmid DNA was added to distilled water to make a final 
volume of 9.6 μL. 0.4 μL of either forward or reverse primer (10 μM) was added to give a final volume 
of 10 μL. DNA sequencing was carried out at the CSC Genomics Laboratory using an automated 
ABI3730xl DNA analyser (Applied Biosystems). Sequences were viewed using 4Peaks (version 1.7) 
and Serial cloner (version 2.6) software (a list of sequencing primers is shown in Table A8). 
 
2.9. RNA expression analysis  
2.9.1. Total RNA purification  
Total RNA was extracted using the RNeasy mini kit (QIAGEN). Cells were plated at a density of 3x105-
5x105 cells per 6 or 10 cm dish and washed with ice cold PBS two days later. All samples were 
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collected in parallel. 350-600 μL of buffer RLT (cell lysis buffer) was added directly to the plate and cell 
lysate was collected using a cell scraper and applied onto a QIAshredder spin column placed on ice. 
All other steps were performed at RT following manufacturer’s guidelines. RNA was eluted in 30–50 
µL RNase-free water into RNase-free tubes. The concentration was determined by measuring the 
absorbance at 260 nm (A260) using a NanoDrop
® ND-1000 UV-Vis spectrophotometer. The RNA was 
stored at –80 °C for future applications. 
 
2.9.2. Gene expression profiling 
2.9.2.1. RNA Quality Control 
Purity and integrity of RNA samples were assessed before microarray analysis. RNA integrity and size 
representation was validated by RT-PCR primed by oligo(dT)18. 1 μg of RNA was used to generate 
cDNA using iScript™ cDNA Synthesis Kit (BioRad) following manufacturer’s instructions. A 1.1Kb 
product was amplified from cDNA by PCR using primers spanning the full-length LUMICAN transcript 
(for a list of cDNA primers see Table A10). PCR products were run on a gel to check amplicon size 
and quantity as described previously. RNA quality was also assessed using the Agilent 2100 
Bioanalyser and Agilent RNA 6000 Nano kit, following manufacture’s guidelines. 28s/18s rRNA ratio 
should be approximately 2.0 An RIN (RNA integrity number) score of above 7 indicates high quality 
RNA extraction (Figure 2.3). 
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Figure 2.3. Bioanalyser profile of acceptable RNA extraction for gene expression profiling.  Profile of RNA 
obtained showing intact and pure RNA with a maximum RIN score of 10. 18S and 28S rRNA peaks are prominent 
with a relatively flat baseline before, in-between and after the two peaks. 
 
2.9.2.2. Microarray analysis 
For microarray experiments, cRNA was hybridized to Human Gene 1.0 ST arrays (Affymetrix) 
following manufacturer’s instructions. Three biological replicates were performed for each condition. 
Microarray data processing and analysis was carried out at EMBL-GeneCore (Heidelberg, Germany).  
Microarray data was normalised using Robust Multichip Average (RMA) and differentially expressed 
genes were identified using Linear Models for Microarray data (LIMMA). A cutoff of a Benjamini-
Hochberg (BH) false discovery rate <0.05 was used to identify significant genes. All analyses were 
carried out in R (v2.13.0).  
 
2.9.3. Quantitative RT-PCR (RT-qPCR) Analysis 
1 μg of RNA was used to generate cDNA using iScript™ cDNA Synthesis Kit (BioRad) following 
manufacturer’s instructions. RT-qPCR reactions were performed on the CFX96™ Real-Time PCR 
Detection System (BioRad) Using SYBR Green PCR Master Mix (Applied Biosystems). Gene 
expression data was normalised to β-glucuronidase (GUS-B) (a list of RT-qPCR primers used is given 
in Table A9). 
 
2.10. Protein expression analysis 
2.10.1. Immunofluorescence  
For immunofluorescence, cells were fixed with 4% PFA (w/v) for 30 min, washed with PBS and 
permeabilised with 0.25% Triton X-100 (v/v) for 10 min. To block unspecific binding of primary 
antibody, cells were incubated for 1 h in blocking solution (0.5% BSA (w/v) and 0.2% fish skin gelatin 
(v/v) in PBS). The cells were then incubated with the primary antibody, diluted in blocking buffer, for 1 
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h at room temperature. Fixed cells were washed three times with PBS (5 min per wash, with agitation) 
to remove unbound primary antibody and were subsequently incubated with the secondary antibody, 
diluted in blocking buffer, for 1 h at room temperature. Cells were washed with PBS three times before 
adding 1 µM DAPI for 10 min for nuclear staining. Stained samples were stored at 4°C in the dark until 
further use (a list of antibodies used is given in Table A11). 
 
2.10.1.1. High throughput microscopy (HTM) 
Immunofluorescence was performed using the IN Cell Analyzer 1000 or 2000 automated high-
throughput microscope (GE Healthcare) with 10x, 20x or 40x objectives. Two or three (where double 
staining is used) fluorescence images were acquired for each field, and fields were distributed 
randomly within each well. A minimum of 500 cells were acquired for each sample per replicate. 
 
2.10.1.2. High content analysis (HCA). 
High content analysis (HCA) was conducted using IN Cell Investigator (v1.7) software (GE Healthcare) 
as described in Banito et al. 2009, DAPI staining of the nuclei was used to identify cells. The nuclei 
were segmented using top-hat segmentation, specifying a minimum nucleus area of 100 μm2. To 
define the cell area, a collar segmentation approach was used with a border of 1 μm around DAPI 
staining. The cellular expression of the analysed protein was determined by measuring the average 
intensity of pixels detected in the reference channel wavelength within the specified nuclear region 
(Object Nuclear Intensity).  
 
Each cell was assigned a nuclear intensity value (and cell intensity value when applicable) for the 
specific protein being studied. A histogram of the nuclear intensity values of the cells in a sample was 
produced and this was used to set a threshold filter to determine positive and negative expressing 
cells (Figure 2.4A). The cut-off for the filter was selected by establishing the negative population on 
the histogram, for example for ARID1B expression - using shARID1B-infected cells (mostly red 
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2.10.1.3. Confocal microscopy 
Coverslips (Fisher Scientific) were treated with 70% ethanol (v/v) for sterilisation and plated in a 10cm 
dish. 106 cells were plated per dish on top of the coverslips and the media was changed the following 
day to remove unattached cells. 2 days after plating, coverslips were fixed with 4% PFA (w/v) for 20 
min and immunofluorescence was conducted as before. Following DAPI staining, coverslips were 
washed twice with PBS and once with water and inverted onto glass slides (Fisher Scientific) with a 
drop of VECTASHIELD® Mounting Media (Vector Labs). Clear nail varnish was used to fix coverslips 
to slides, and slides were left to dry for 20 min. Fluorescence Images were taken with the Leica SP5 
confocal microscope using the 40x objective. 
 
2.10.2. SILAC to identify changes in protein expression  
Stable isotope labelling with amino acids in cell culture (SILAC) is a method used to identify differential 
changes in proteins by mass spectrometry-based quantitative proteomics. Early passage IMR90 cells 
were grown for two passages in SILAC media containing either ‘light’ or ‘heavy’ amino acids, to allow 
production of newly synthesised labelled proteins. 500 mL of SILAC DMEM (Thermo Fisher Scientific 
(89985)) and was supplemented with either 50 mg of Light-Arginine and Light-Lysine or 50 mg of 
Heavy-Arginine (L-Arginine-HCl, 13C6, 15N4, 89990, Thermo Fisher Scientific) and Heavy-Lysine (L-
Lysine-2HCl, 13C6, 15N2, 88209, Thermo Fisher Scientific). Media was supplemented with 10% 
Dialyzed FBS for SILAC (89986, Thermo Fisher Scientific) and Antibiotic-Antimycotic as before. Cells 
were transduced with virus suspended in SILAC complete medium and two days later were split for 
selection in SILAC complete medium supplemented with 0.5 μg/mL puromycin for 7 days. In total cells 
were grown in SILAC media for a minimum of three passages. 
 
2.10.2.1. Whole cell protein extraction  
SILAC labelled cells were counted and equal numbers of ‘heavy’ and ‘light’ cells (approximately 5x106 
cells each) were mixed together and pelleted by centrifugation. Cell pellets were washed once with ice 
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cold PBS and were resuspended in RIPA buffer (1% NP-40, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 0.5% Sodium Deoxycholate, 1 mM EDTA) supplemented with protease inhibitors. Cells 
were incubated on ice for 30 min and cell lysates were subjected to centrifugation for 15 min at 
maximum speed. The supernatant containing proteins was transferred to a fresh tube. 
 
2.10.2.2. Protein quantification 
Proteins were quantified using the DC Protein Assay (BioRad) in a microtitre 96-well plate following 
manufacturer’s guidelines for microplate assay. Absorbance at 660 nm (A660) was measured using the 
Bio-Rad 680XR. Protein concentration was determined relative to known standards prepared in the 
same buffer as analysed samples. 70 μg of protein was used for analysis of proteins differentially 
expressed using SILAC whole cell extracts. 
 
2.10.2.3. Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
Protein samples were diluted with 5x Laemmli sample buffer (1x concentration; 60 mM Tris-Cl pH 6.8, 
2% Sodium-dodecyl-sulphate (SDS, w/v), 10% glycerol (v/v), 5% β-mercaptoethanol (v/v), 0.01% 
bromophenol blue(w/v)) and were heated at 90°C for 7 min. Following a brief centrifugation step 
samples were loaded onto a 10% Mini-PROTEAN® TGX™ Precast Gel (BioRad) in running buffer (25 
mM Tris, 190 mM Glycine, 0.1% SDS (w/v)). Electrophoresis was conducted at 100V for 15-20 min to 
allow sample to just enter the resolving gel. Proteins were fractionated alongside Precision Plus 
Protein™ Dual Color Standards (BioRad) as a reference. After resolving, the protein gel was washed 
3 times in distilled water for 5 min each with gentle agitation. Proteins were stained for visualisation 
with Coomassie Brilliant Blue R-250 (BioRad) for 6 h and washed with copious amounts of water over 
night.  
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2.10.2.4. Co-immunoprecipitation of nuclear protein complexes 
To identify changes in nuclear complexes in senescent cells, proteins were labelled using SILAC as 
before. Equal numbers of cells were counted and mixed (approximately 1.5x107 cells per condition) 
and nuclear material was extracted using the Nuclear Complex Co-IP Kit (Active Motif) following 
manufacturer’s recommendations. 5% of the nuclear fraction was kept as “input” to assess the mixing 
error and the remainder was halved to immunoprecipitate ARID1B complexes and isotype matched 
IgG (as a negative control) at 4°C overnight. The next day 50 μL of magnetic beads coupled with 
recombinant protein G (Dynabeads® Protein G, Invitrogen) was added to each sample for 4 h at 4°C. 
Bound complexes were washed using magnetic recovery of beads following manufacturer’s 
guidelines, and eluted in 30 μL of 5x Laemmli sample buffer by heating at 90°C for 10 min. 
Immunoprecipitated protein samples were subjected to SDS-PAGE as described previously. 
 
2.10.2.5. Identification of proteins by LC–MS/MS 
Mass spectrometry and peptide quantification analysis was performed in the Biomolecular Mass 
Spectrometry and Proteomics Laboratory (CSC). Gel bands were reduced with dithiothreitol, alkylated 
with iodoacetamide and then subjected to overnight trypsin digestion. The peptide extracts underwent 
a second round of trypsin digestion to minimise the number of missed cleavages. Peptide mixtures 
were analyzed using an UltiMate 3000 Rapid Separation LC, coupled to a LTQ-Orbitrap-Velos mass 
spectrometer (ThermoFisher Scientific). Separation was performed in a 3 h gradient using a 50 cm 
Acclaim pepmap C18 column (ThermoFisher Scientific). Protein identification and quantification was 
performed using Maxquant v1.2.0.13, with the embedded Andromeda 1.2.0.0 search engine and the 
IPI_Human_v3.37 database. The initial minimum ratio H/L count was set to 1 to obtain raw data, 
however the stringency was later increased to a minimum  count of 3.  
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For identification of ARID1B associated proteins, further stringency parameters were included. 
Confident interactors were defined as proteins that had a total count higher than that obtained in the 
5% input and cytoplasmic proteins were excluded from the final list. 
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Chapter 3. Screening for regulators of lifespan extension in 
MEFs using NGS 
 
Functional shRNA screens combined with NGS has led to the discovery of important regulators of 
various cellular processes including senescence and cell proliferation (Burrows et al., 2010; Silva et 
al., 2008). In order to identify novel genes involved in the regulation of senescence, an shRNA 
screening coupled to NGS was planned. Many conditions must be optimised prior to conducting 
shRNA screenings including the size of the shRNA pools to be tested and the duration of the screen. 
 
3.1. Optimisation of the bypass of senescence screening  
To screen for regulators of replicative senescence in MEFs, assay conditions must first be optimised. I 
used a relatively small shRNA library to screen for senescence regulators in MEFs, to establish the 
screening protocol using NGS. The HCC shRNA library consists of 624 shRNAs and was provided by 
Lars Zender. The library contains mouse orthologues of genes frequently deleted in approximately 100 
human HCC tumours. 58 regions in the genome were recurrently deleted, and these regions held 362 
genes. Of these 362 genes, 301 mouse orthologues were identifiable and corresponding shRNAs 
were obtained from the Cold Spring Harbor Laboratory RNAi CODEX library (Figure 3.1A). Hairpins 
were shuttled from the pSM2 vector to pLMS which contains GFP expression to allow identification of 
infected cells (Figure 3.1B). 624 shRNAs were divided into 13 pools each containing 48 shRNAs; each 
deleted gene was therefore represented by 2 mouse shRNAs on average. 
 
The HCC library has previously been used to identify tumor-promoting shRNAs in a mouse model of 
HCC (Zender et al., 2008). The advantage of using this library, as opposed to a library of randomly 
pooled shRNAs, is that the library contains genes deleted in cancer and therefore may be enriched for 
important tumour suppressors. 
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improve the reliability of the screening and decrease the number of false positives obtained, the 
screening was conducted in biological triplicate. For each independent replicate MEFs were infected 
at passage 1. 4 days later, cells were trypsinised and counted. 4x105 cells were plated in duplicate 
and the remaining cells were collected for genomic DNA extraction, DNA from this aliquot was 
assigned as the reference sample. Cells were passaged and a fraction of the cells were collected at 
days 6 (passage 2), 10 (passage 3), 15 (passage 4) and 26 (passage 5) (Figure 3.3A). 
 
Genomic DNA was extracted from cells and the hairpin sequences integrated into the genomic DNA 
were recovered by PCR amplification (Figure 3.3B). PCR primers were designed such that the 
extreme 5’ and 3’ ends of the final PCR product are complementary to the sequence of the Solexa 
flow cell adaptors, allowing the amplified PCR product to hybridise to the Solexa flow cell (Figure 
3.3B). Each sample (biological replicates and time points) was assigned a specific 3 nt barcode, 
incorporated into the 5’ PCR primer which allows shRNA reads amplified from the same sample to be 
identified. All barcoded samples were combined in equal amounts and sequenced on the same lane of 
the Solexa flow cell.  
 
Sequencing of samples from the HCC screen was conducted at the Helmholtz Centre for Infection 
Research (HZI, Germany) in the first instance and later at the Clinical Sciences Centre (CSC, UK) to 
verify the sequencing protocol. Solexa libraries at the CSC were sequenced on the Illumina GAIIx 
using a 39 bp cycle run. Primers were slightly modified from the conventional primers used for miR30 
shRNA recovery (Sims et al., 2011; Zender et al., 2008) to allow the full hairpin plus barcode to be 
sequenced within 39 bp (Figure 2.2). In a test-sequencing run at the CSC, 6 pM of Solexa library was 
run on 2 lanes of a single flowcell. On average, over 107 reads were recovered per lane, with perfect 
hairpin alignment to miR30 shRNA libraries, and with perfect barcode sequencing match (Figure 
3.3C).  
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Comparison of enriched hairpins detected from the same Solexa library run on two different lanes of a 
flowcell, shows there is very little variability in the sequencing output between the lanes (variation may 
arise during the clustering step involving bridge amplification) (Table A1). Variation between lanes is 
higher in ‘Day 0’ samples where all shRNAs in a sample are relatively equally distributed, and 
variability is almost minimal in ‘Day 26’ samples, which contain enriched hairpins (Table A1). 
Sequencing of ‘Day 0’ samples verified that the number of shRNAs detected in the test sequencing 
run is comparable to the number detected in the HZI sequencing run (Figure 3.3D). 
 
The test-sequencing run allowed verification of the establishment of an NGS protocol for massive 
parallel sequencing of miR30 shRNAs using a 39 cycle base run. On average, 7.3x105 sequencing 
reads per sample can be obtained from a screen with 5 time-points, conducted in triplicate (a total of 
15 samples). For screenings using the pooled HCC deletion library, this allows each shRNA to be 
represented on average over 1,000 times in each of the 15 samples.  
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3.4. ARID1B is a candidate regulator of replicative senescence in MEFs 
Sequencing data from the screen was analysed by measuring the enrichment of a gene across the 
entire dataset. Sequencing data has been represented as pie charts to show the relative abundance of 
particular shRNAs within a sample (Figure 3.4A). This representation shows there is no initial library 
bias as reference samples (Day 0) have a similar distribution of all shRNAs whereas in later time-
points there is a change in the distribution (Figure 3.4A).  
 
Z-scores were first calculated to assess the distribution of shRNA sequences in each sample. From 
this a p-value was given. To analyse the enrichment of shRNAs, each gene was assigned a Fisher’s 
combined p-value, which allows the independent p-values across all samples to be combined (Figure 
3.4B). Arid1b was identified as the gene with the most significant Fisher’s combined p-value as it was 
frequently enriched in different time-points and in different replicates (Figure 3.4A red asterisks, Figure 
3.4B). Furthermore, independent shRNAs targeting Arid1b were also found in the screen (Figure 3.4A 
Replicate 2, day 6, red asterisks) suggesting that Arid1b is a strong candidate implicated in replicative 
senescence in MEFs. 
 
ARID1B is a component of the SWI/SNF complex of nucleosome remodellers. This complex is 
involved in numerous cellular processes and its subunits are frequently mutated in cancer 
(Hargreaves and Crabtree, 2011). Previous studies on ARID1B have shown that it plays an important 
role in differentiation (Nagl et al., 2007; Yan et al., 2008) and that it is involved in transcriptional 
regulation of cell cycle effectors p21CIP1 and c-myc (Inoue et al., 2011). However a role for Arid1b in 
senescence regulation has not been previously identified. 
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3.5. Depletion of Arid1b extends cellular lifespan in MEFs 
To confirm the role of Arid1b in lifespan extension, three hairpins targeting Arid1b were designed and 
cloned, of which, one hairpin produced an efficient knockdown of Arid1b at the protein level and 
mRNA level (Figure 3.5A, B). Knockdown of Arid1b resulted in an observable increase in colony 
formation (Figure 3.5D) and extended the replicative lifespan of MEFs (Figure 3.5C). The data 
confirms the result from the screening and suggests that Arid1b knockdown delays senescence in 
MEFs. 
 
3.6. ARID1B regulates cell proliferation and replicative senescence in IMR-90 
In order to establish whether the effect of Arid1b was more general and conserved in humans, three 
independent shRNAs targeting human ARID1B mRNA were designed. The efficiency of ARID1B 
knockdown was judged by RT-qPCR and by immunofluorescence. Both shARID1B-2 and shARID1B-3 
resulted in significantly depleted ARID1B expression; however shARID1B-3 had a greater knockdown 
efficiency than shARID1B-2 (Figure 3.6A, B). Knockdown of ARID1B increased the lifespan of IMR-90 
cells (Figure 3.6C) and also increased the ability of these cells to form colonies at low density (Figure 
3.6E). The efficiency of ARID1B knockdown, correlated with the ability to delay senescence. These 
experiments confirm that ARID1B ablation extends cellular lifespan of both human and mouse 
fibroblasts. 
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3.7. Conclusions and perspectives 
3.7.1. Screening for regulators of replicative senescence in MEFs 
Genetic screenings for the bypass of senescence have served to identify genes associated with 
cancer (Acosta et al., 2008; Burrows et al., 2010; Gil et al., 2004). In this work I used a small HCC 
shRNA library to establish a protocol for senescence screenings coupled to NGS. The screening was 
conducted in primary MEFs which have a limited replicative lifespan and quickly undergo senescence 
attributed to high levels of oxidative stress, a phenomenon known as ‘culture shock’ (Parrinello et al., 
2003; Sherr and DePinho, 2000). The HCC shRNA library used was well suited for this purpose, the 
library is relatively small (624 shRNAs) and therefore pooled shRNA screens can be conducted with 
relative ease, and the sequencing data obtained had a high depth of coverage, with each shRNA 
represented on average 1000 times in 15 different time-points and replicates. Furthermore, the library 
targets genes that are frequently deleted in human HCC, and therefore the HCC library is enriched for 
tumour suppressor genes that may have a role in senescence. Indeed, the library has previously been 
used to identify novel HCC tumour suppressor genes as well as genes involved in liver regeneration 
(Wuestefeld et al., 2013; Zender et al., 2008).  
  
The limited replicative lifespan of MEFs has served as a valuable system for identifying senescence 
regulators (Jacobs et al., 2000; Leal et al., 2008; Shvarts et al., 2002). A potential problem of using 
MEFs in a lifespan extension screen is that mutations accumulate in MEFs upon prolonged culture, 
which allows escape from senescence (Busuttil et al., 2003). These mutations give rise to dense 
highly proliferating colonies. Such colonies may be infected with ‘passenger’ shRNAs which will 
become enriched and therefore will contribute to ‘false positive’ candidates. At day 26 the control cells 
were not substantially affected by dense colony formations arising from clonal variation and therefore 
day 26 was chosen as a suitable end time point for the screening.  
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To confirm that ARID1B is a true regulator of senescence, it was important to reproduce the result of 
the senescence bypass observed in MEFs. For this purpose a mouse shArid1b hairpin was created 
that had an independent target sequence to the hairpins in the HCC library. This independent hairpin 
also extended the cellular lifespan of MEFs. A similar growth advantage was seen when ARID1B was 
depleted in late passage IMR-90 cells. Taken together the data suggests that ARID1B has a role in 
senescence. 
 
3.7.2 Advances in pooled shRNA screenings using NGS 
Over the last decade the speed, lowered costs and data output of NGS has progressed rapidly and 
massive parallel sequencing has been adapted for use with a number of different techniques. NGS 
has previously been used to identify shRNAs from pooled library screenings (Schlabach et al., 2008; 
Silva et al., 2008). Here I established a protocol for use of NGS to identify miR30 based shRNAs on a 
39 bp GAIIx Solexa run. For this purpose, PCR primers were adjusted from conventional primers 
(Sims et al., 2011; Zender et al., 2008) to permit sequencing of the full hairpin and barcode in 39 bp. 
 
Conditions were optimised to maximise data output. Initially, the amount of DNA loaded onto flow cells 
for bridge amplification (clustering) was tested. Accurate measurement of the concentration of the 
template library is critical to maximise the cluster density while simultaneously avoiding cluster 
detection issues due to overcrowding and cluster focusing. An initial sequencing run tested 8 pM and 
6 pM based on the sample concentrations used previously for ChIP-sequence. 6 pM produced the 
highest number of clusters passing filter (254204 compared to 197931) and was used for sequencing 
runs thereafter. I also assessed the variability due to clustering by comparing the highest-ranked 
hairpins from the same Solexa library run on two different lanes of a flowcell. I detected very little 
variability in the highest ranked hairpins confirming that variation in cluster generation does not 
substantially affect the ranking of hairpins detected. 
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The Solexa sequencing primer begins sequencing within the variable region of the hairpin. It is 
important that the first four bases of the amplicon have no sequence bias as these sequencing cycles 
are used to detect the position of all the clusters and to calculate expected signal intensities for each 
channel, which should be equal for the four bases (A, T, C and G). Samples which have an even 
distribution of the four bases across the run are ‘high-diversity’ whereas samples which have a 
sequence imbalance (i.e. high levels of certain bases in certain positions) are ‘low-diversity’. 
Sequencing libraries from senescence screenings may contain bias as some shRNAs are expected to 
be enriched in the sample, especially at later time points and therefore the distribution of the four 
bases will not be even. When low-diversity samples are being sequenced a control lane is run parallel 
to the samples to set up sequencing and alignment. This control lane sequences DNA from ‘PhiX’ a 
high-diversity viral genome. The Genomics facility found the PhiX control lane is essential for obtaining 
reads with a high percentage pass filter rate. They also tested using a PhiX “spike” in the sample, 
which is less expensive then sequencing a separate control lane; however this decreased the number 
and quality of the amplicons obtained. 
 
The swift advances in NGS technology means that protocols must be continuously optimised to suit 
upgrades in machines and improvements in reagents. In most institutes, including the CSC, the GAIIx 
has been replaced by the HiSeq 2000, which no longer has the option of 39 bp reads. The minimum 
read length of 50 bp will increase the percentage of perfectly matched reads, as hairpins sequenced 
using 50 cycle sequencing kits will not be affected by the drop in peak intensity due to limited reagents 
when the run is nearing completion. Obtaining a high read accuracy at the end positions of the 
sequence is critical as sample barcodes are situated there. Using a longer cycle run also allows longer 
barcodes to be used. In this way, barcodes can be designed to be redundant, such that single base 
mismatches within the barcode region would still allow for correct identification of the amplicon to the 
corresponding sample, therefore lowering the percentage of discarded reads. The HiSeq 2000 is able 
to produce 4.5 GB of data per 50 bp sequencing lane compared to 1 GB of data per 39 bp lane on the 
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GAIIx. The increased data output makes the HiSeq 2000 better suited for genome-wide shRNA 
screens. However this comes at a greater overall cost of £500 compared to £371 for the GAIIx. For 
screenings using small shRNA libraries the GAIIx may still be the most cost-effective method of 
sequencing however with the advent of the HiSeq 2500 (August 2012), it is likely that the GAIIx will 
soon be replaced. 
 
As the popularity of pooled shRNA screenings using NGS has increased, a number of statistical 
packages have become available for analysing data from high-throughput screens (Sims et al., 2011; 
Yu et al., 2013). This will aid processing the increasing amounts of data retrieved from NGS 
screenings. Packages can be modified to suit the preferences of the user, for example in our 
screenings only reads with perfect alignment to the reference library were selected, however others 
have allowed reads with up to two mismatches to pass filter (Sims et al., 2011). As with statistical 
packages, the number of commercial shRNA libraries available is also increasing. Efforts are now 
focused on developing validated genome-wide libraries which will ease the use of shRNA screens, 
especially in vivo when smaller pools containing potent shRNAs are required (Fellmann et al., 2011). 
The rapid advances in RNAi and NGS means that large pooled shRNA screenings have become a 
powerful and widely available tool to identify regulators of important pathways in vitro and in vivo.  
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Chapter 4. ARID1B a component of the SWI/SNF complex 
regulates senescence 
 
4.1. Knockdown of ARID1B attenuates OIS 
The ability of ARID1B knockdown to delay replicative senescence in primary mouse and human 
fibroblasts led to the investigation of the role of ARID1B during OIS. For this purpose, IMR-90 ER:RAS 
cells were infected with ARID1B shRNAs and control constructs. When compared to vector infected 
cells, cells with ARID1B knockdown proliferated faster (Figure 4.1A, D). ARID1B knockdown also 
resulted in an increase in the percentage of replicating cells as measured by BrdU incorporation. To 
understand whether this increase in proliferation was due to a bypass in senescence, cells were 
stained for SA-β-Gal activity to identify senescent cells (Dimri et al., 1995). As expected the 
percentage of SA-β-Gal positive cells increased when IMR-90 ER:RAS cells were treated with 4OHT 
(Figure 4.1C, D). ARID1B depleted cells had lower SA-β-Gal activity compared to vector cells (Figure 
4.1C, D). Together these results suggest that ARID1B is an important regulator of OIS. 
 
4.2. ARID1B regulates p21CIP1, p16INK4a and p53 expression during OIS 
OIS is mediated by different senescence effectors, including p21CIP1, p16INK4a, and p53. As ARID1B 
knockdown abrogates OIS, it is important to understand its effects on these pathways. I compared the 
expression of these senescence effectors using quantitative IF. P21CIP1, p16INK4a and p53 expression 
was lower when ARID1B was depleted during OIS (Figure 4.2A-D). Knockdown of ARID1B also 
decreased the mRNA levels of CDKN1a and INK4a during OIS demonstrating that ARID1B regulates 
the expression of important cell cycle regulators (Figure 4.2E, F). 
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4.3. Gene expression profiling identifies multiple senescence effectors regulated by 
ARID1B 
To further elucidate the mechanisms by which ARID1B controls senescence, I analysed the gene 
expression profile of cells undergoing OIS. For this purpose I used IMR-90 ER:RAS cells infected with 
empty vector or shARID1B-3 and induced senescence (by addition of 4OHT). 6 days later RNA was 
collected for gene expression profiling using the Human Gene 1.0 ST arrays (Affymetrix).  
 
A total of 108 genes were identified, in which transcript levels were either up- or down-regulated by at 
least 2-fold in ARID1B knockdown cells compared to vector cells. Genes downregulated by at least 2 
fold during ARID1B knockdown include components of the SASP including SPP1 (OPN) and MMP3. 
Genes upregulated by at least two-fold when ARID1B is depleted include the p16INK4a inhibitor ID1 as 
well as ID2 and ID3 (Table A2). The expression levels of other genes relevant for senescence were 
also ablated upon ARID1B knockdown including ETS1, GDF15, E2F7 and CDKN1a (Table A.2). 
Interestingly, many proteins associated with keratinocyte differentiation including four members of the 
Late cornified envelope (LCE) gene cluster on chromosome 1q and two members of the Keratin–
associated protein 2 (KRTAP2) gene cluster on chromosome 17q were also significantly 
downregulated (Table 4.1). Some of these gene expression changes were investigated by RT-qPCR 
in IMR-90 ER:RAS cells infected with either vector, shARID1B, shp53 and shp16 (Figure 4.3). This 
data served to confirm that ARID1B ablation during OIS results in gene expression changes in 
important senescence pathways.  
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4.4. Expression of oncogenic PIK3CAH1047R induces senescence 
As previously discussed, aberrant activation of the PI3K pathway induces a stable senescence 
response (Astle et al., 2012; Steelman et al., 2011). To study the effect of ARID1B on PI3K induced 
senescence, I first overexpressed several PIK3CA mutants (data not shown). One such mutant, 
PIK3CAH1047R, harbours a mutation in the PIK3CA kinase domain resulting in constitutive activation of 
the kinase (Ligresti et al., 2009). To test if PIK3CAH1047R induces senescence, I infected IMR-90 cells 
with PIK3CAH1047R, mutant RASG12V or a control. Activation of PI3K was investigated by measuring the 
phosphorylation status of AKT (a downstream target of PI3K) using quantitative IF. PIK3CAH1047R 
expressing cells had elevated levels of phospho-AKT (Serine 473) when compared to vector 
expressing cells confirming that the PIK3CAH1047R mutant is active (Figure 4.4.1A). In response to 
PIK3CAH1047R expression, IMR-90 cells adopted a flattened, enlarged morphology with numerous 
vesicles contained within the cytoplasm and cell growth was limited substantially compared to vector 
cells (Figure 4.4.1B, C and Figure 4.5C). PIK3CAH1047R infected cells also displayed a higher level of 
SA-β-Gal activity when compared to vector infected cells. However the levels of SA-β-Gal activity 
were lower than that observed in RASG12V expressing cells (Figure 4.4.1D). Therefore expressing 
PIK3CAH1047R can induce senescence in IMR-90 cells. 
 
Recently, ARID1B was identified as a cancer gene, frequently mutated in breast cancer (Stephens et 
al., 2012). Tumours harbouring ARID1B mutations were also associated with mutations in PIK3CA 
and PTEN, suggesting possible cooperation between ARID1B mutations and abrogated PI3K 
signalling during tumourigenesis . Similarly in ovarian clear cell carcinoma (OCCC), ARID1A mutations 
occur in 57% of tumours (Jones 2010).  Loss of ARID1A frequently coexists with PIK3CA mutations in 
OCCC, suggesting that these events are not mutually exclusive (Jones et al., 2010; Yamamoto et al., 
2012a, b). 
 
106   
To further characterise the senescence response observed upon PIK3CAH1047R expression. IMR-90 
cells infected with control, mutant PIK3CAH1047R or mutant RASG12V were subjected to quantitative IF. 
Protein expression of p16INK4a, p21CIP1 and p53 increased upon PIK3CAH1047R expression; however 
levels of the effectors were not as high as that induced by RASG12V (Figure 4.4.2A). Similar results 
were observed by RT-qPCR (Figure 4.4.2B). In conclusion, a senescence response is induced by 
ectopically expressing PIK3CAH1047R. 
 
4.5. Knockdown of ARID1B attenuates PIK3CAH1047R mediated senescence 
To test if ARID1B has a role in PIK3CAH1047R mediated senescence, I investigated the effect of 
ARID1B knockdown in PIK3CAH1047R expressing cells. IMR-90 were double infected with either mutant 
PIK3CAH1047R or empty vector and with hairpins targeting either ARID1B or control hairpins. 
PIK3CAH1047R expressing cells, infected with shARID1B-3, had a higher percentage of BrdU positive 
cells and formed more colonies at low density compared to control PIK3CAH1047R expressing cells, 
confirming that ARID1B depletion increases proliferation in PIK3CAH1047R expressing cells (Figure 
4.5A, B). Furthermore, cells appeared less flat and contained less vesicular structures when ARID1B 
was knocked down during PIK3CAH1047R induced senescence (Figure 4.5C). PIK3CAH1047R expressing 
cells with p16INK4a knockdown were able to form highly dense colonies, which did not appear to be 
contact inhibited (Figure 4.5C). Together these data suggest that ARID1B is important in PIK3CAH1047R 
mediated senescence. 
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4.6. ARID1B regulates p16INK4a and p21CIP1 expression during PIK3CA-induced 
senescence 
I next investigated whether the senescence bypass mediated by ARID1B knockdown in PIK3CAH1047R 
expressing cells is similar to that seen in RAS expressing cells when ARID1B is depleted. Quantitative 
IF and RT-qPCR was used to assess changes in levels of p16INK4a and p21CIP1 in ARID1B ablated 
cells. As with OIS, the levels of both CDKIs decreased when ARID1B was depleted in cells expressing 
PIK3CAH1047R suggesting ARID1B controls gene expression of CDKN1a and INK4a during PIK3CA-
induced senescence (Figure 4.6A-C). 
 
4.7. High expression of SWI/SNF complex components during replicative 
senescence 
As ARID1B knockdown delays senescence, I next asked whether the levels of ARID1B change as 
cells approach senescence. In young IMR-90 (passage 11), ARID1B expression was low and 
gradually increased during replicative senescence (from passage 19 to passage 26), as detected by 
immunofluorescence (Figure 4.7A). Similar changes were observed with core SWI/SNF components 
BRG1, BRM and SNF5 (Figure 4.7A). Furthermore, ARID1B levels also increased upon serial 
passage of MEFs (Figure 4.7B).   
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4.8. Expression of SWI/SNF complex components increases during OIS 
To see if the expression of SWI/SNF components is increased during OIS, Iassessed the levels of 
SWI/SNF proteins in IMR-90 and MEFs expressing RASG12V. I found that cells expressing RASG12V 
displayed elevated protein levels of certain SWI/SNF components (Figure 4.8A, B). Elevated SWI/SNF 
protein levels were also detected during PIK3CAH1047R induced senescence, and ARID1B levels also 
increase in IMR-90 ER:RAS cells upon 4OHT treatment (data not shown). In contrast quiescent cells, 
arrested by serum starvation, show similar levels of SWI/SNF proteins to proliferating cells (Figure 
4.8A). Taken together the data indicates there are increased levels in SWI/SNF proteins during 
senescence consistent with a recent study demonstrating the upregulation of chromatin-associated 
BRG1 in cells expressing RASG12V (Tu et al., 2013). I also show that this is not associated with 
reversible forms of cell cycle arrest but is specific to senescence. 
 
4.9. Post-translational stabilisation of the SWI/SNF complex during senescence 
I next sought to investigate if the increase in SWI/SNF levels during senescence was mediated by 
changes in transcription. For this purpose I conducted RT-qPCR analysis in senescent cells and non-
senescent cells using primers specific to SWI/SNF subunits and to senescence associated CDKIs as 
a control (Figure 4.9A, B). Furthermore, I utilised data from gene expression profiling to assess the 
differential gene expression of IMR-90 ER:RAS cells undergoing OIS (Figure 4.9C). In both cases, 
mRNA levels of the majority of SWI/SNF subunits remained constant during both replicative 
senescence and OIS, suggesting that the increase in SWI/SNF expression during senescence is 
regulated post-transcriptionally. 
114   
????
  
?????
  
4.10. SILAC based quantitative proteomics identifies changes in the levels of 
ARID1B binding proteins during OIS 
As previously described, mammalian SWI/SNF complexes undergo subunit exchange during 
differentiation and other processes (Takeuchi and Bruneau, 2009; Wang et al., 1996a; Yoo et al., 
2009).  To further understand how the complex functions it is important to identify the composition of 
the complex and its interactors. Quantification of protein-protein interactions is favourable to 
discriminate specific interactions from background binding (Vermeulen et al., 2008). SILAC can be 
used to quantify changes in SWI/SNF subunit compositions in different cell types (Ong et al., 2002). 
Co-immunoprecipitations (co-IPs) coupled to MS have previously facilitated the discovery of the 
esBAF, npBAF and nBAF complexes (Ho et al., 2009b; Wu et al., 2007; Yoo et al., 2009). It is 
therefore worth investigating if a ‘senescence-associated SWI/SNF complex’ exists or whether there is 
an indiscriminative upregulation of all subunits associated with the complex. Furthermore, it may be 
possible to determine if the post-transcriptional increase in various SWI/SNF proteins is due to 
stabilisation of the complex via interactions with other proteins specifically in senescence.  
 
SILAC-IPs were performed to identify changes in proteins interacting with ARID1B in cells infected 
with either RASG12V or vector (Figure 4.10A). Importantly a “5% input” sample was taken to assess the 
mixing error and to determine if a protein was enriched in the immunoprecipitated sample (Figure 
4.10A). ARID1B immunoprecipitation antibody was validated by performing IP-Western using two 
ARID1B antibodies that recognize different epitopes (Figure A1.A). Similarly the ability to co-
immunoprecipitate SWI/SNF components was tested by performing an ARID1B IP followed by BRG1 
detection using Western blot (Figure A1.B). Initial analysis of the data indicated that the IPs were 
specific, detecting all core components of the SWI/SNF complex (BRG1, BRM, SNF5, BAF155, 
BAF170). As expected, mutually exclusive subunits, ARID1A and PBAF specific peptides (PBRM1, 
ARID2, BRD7, BAF45A) were not detectable in ARID1B IPs however were present in similar IP/MS 
performed with BRG1 (data not shown).  
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 Although the IPs did not show a change in the levels of most SWI/SNF components during OIS, a 
number of proteins were associated with ARID1B preferentially during OIS (Figure 4.10B). Strikingly, 
proteins with the greatest increase in ARID1B binding in RASG12V expressing cells were associated 
with the nucleolar compartment (KRI1, KRR1, RRP8, NO66, LYAR), which may reflect an overall 
change in nucleolar structure during OIS (Narita et al., 2003a) (Figure 4.10B). Some of the detected 
proteins shown to interact with ARID1B were involved in cell proliferation including Ly1 antibody 
reactive (LYAR), putative ribosomal RNA methyltransferase (NOP2), Lamin-A (LMNA) eukaryotic 
initiation factors 3D and 3E (EIF3D, EIF3E) and regulator of chromosome condensation 2 (RCC2), 
(Figure 4.10B) (Fonagy et al., 1994; Huang et al., 2008b; Mollinari et al., 2003; Su et al., 1993; 
Watkins and Norbury, 2004). 
 
Further SILAC-IPs were conducted to establish proteins associated with ARID1B in cells 
overexpressing ARID1B. The majority of the SWI/SNF complex was enriched in the pull downs when 
ARID1B is expressed; notably the only isoform of BAF45 that was enriched when ARID1B is 
overexpressed was BAF45D (Figure 4.10C) and this protein together with KRI1 homologue (KRI1) 
and NFκB repressing factor (NKRF) were found enriched in the complex in both RASG12V and ARID1B 
expressing cells (Figure 4.10B, C). The majority of the proteins interacting with ARID1B were 
associated with transcription and elongation, in support of previous evidence for a role of SWI/SNF in 
this process (Drost et al., 2010; Staal et al., 2000). 
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4.11. ARID1B is excluded from regions of repressed chromatin 
As ARID1B was shown to bind to a number of transcriptional regulators, it was of interest to dissect 
the relationship between ARID1B and active or repressed chromatin. In particular it was recently 
shown that BRG1 is an important factor required for SAHF formation (Tu et al., 2013), and that 
overexpression of SWI/SNF subunits increases the formation of SAHFs (Figure 4.13.2) (Tu et al., 
2013). SAHFs can be identified by the presence of H3K9me3 and H3K27me3 layers at the site of 
condensed heterochromatin (Chandra et al., 2012; Narita et al., 2003a). To identify the correlation 
between ARID1B and SAHFs, cells expressing RASG12V were probed with antibodies targeting either 
H3K9me3 or H3K27me3 simultaneously with ARID1B (Figure 4.11A). Expression of RASG12V in IMR-90 
human fibroblasts resulted in the formation of SAHFs and the presence of a single large nucleolus as 
previously described (Figure 4.11A) (Narita et al., 2003a). Interestingly, ARID1B appeared to be 
excluded from SAHFs as shown by confocal imaging (Figure 4.11A). Fluorescence intensity profiles 
demonstrated the non-overlapping nature of ARID1B with both H3K9me3 and H3K27me3 (Figure 
4.11A). In particular areas stained with ARID1B were void of the H3K27me3 mark, suggesting that 
ARID1B is generally associated with active chromatin (Figure 4.11A white arrow heads).  
 
In support of this notion, growing cells were probed with BrdU, to identify sites of DNA replication, that 
correlate with H3K27me3, in IMR-90 (Chandra et al., 2012). Similarly to H3K27me3 staining, ARID1B 
was shown to exclude BrdU staining and vice versa (Figure 4.11B white arrow heads). This data, 
together with the binding of ARID1B to proteins involved in transcription and elongation, suggest 
ARID1B is associated with active chromatin regions.  
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4.12. Retroviral constructs overexpressing ARID1A and ARID1B 
As components of the SWI/SNF complex are induced during senescence, it was important to 
determine the effect of overexpression of SWI/SNF proteins in young IMR-90 cells. For this end, 
retroviral vectors expressing ARID1A and ARID1B were cloned. The expression of proteins from these 
vectors was first verified by quantitative IF (Figure 4.12A, B). Expression of ARID1A and ARID1B was 
simultaneously probed using antibodies raised in different species. Interestingly the results showed 
that overexpression of ARID1B resulted in a significant decrease in ARID1A protein levels (Figure 
4.12A, B). A similar effect was not seen at the transcriptional level, as overexpression of ARID1B did 
not significantly change ARID1A mRNA levels. The data verifies that ectopic expression of ARID1A 
and ARID1B retroviral constructs increases the levels of the respective proteins at both the protein 
and RNA level.  
 
4.13. Ectopic expression of SWI/SNF subunits induces premature senescence 
To complement the findings observed using ARID1B shRNAs, ARID1B and other SWI/SNF proteins 
were ectopically expressed to explore their effects on cell proliferation. Expression of SWI/SNF 
components in IMR-90 cells caused a reduction of cell growth and cells exhibited characteristic 
features of senescence (Figure 4.13.1-2). The induction of growth arrest was confirmed by colony 
formation assays, and by the appearance of enlarged flat cells (Figure 4.13.1A). Although in IMR-90 
human fibroblasts the SWI/SNF induced growth arrest was not as striking as that produced by 
RASG12V, the proportion of cells staining positively for SA-β-Gal activity increased greatly from <1% in 
vector expressing cells to around 36-47% in cells expressing various components of the SWI/SNF 
complex (Figure 4.13.1A).  
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the p53/p21CIP1 pathway (Drost et al., 2010; Dunaief et al., 1994; Guan et al., 2011; Inoue et al., 2011; 
Lee et al., 2002a). 
125   
??
????
  
4.14. Premature senescence Induced by ARID1B is mainly p53 dependent 
As ARID1B regulates the levels of p53 and p21CIP1 in HeLa cells (Inoue et al., 2011), and induces 
p21CIP1 and p16INK4a expression in IMR-90 human fibroblasts (Figure 4.13.2), it was important to 
explore the role of various senescence effectors in ARID1B-mediated growth arrest. For this purpose 
ARID1B was expressed together with hairpins targeting either p21CIP1, p16INK4a, p53 or an empty 
vector to act as a control. The knockdown efficiency of the hairpins was tested by RT-qPCR (Figure 
4.14.1D).  
 
Knockdown of p21CIP1 and p16INK4a partially alleviated the growth arrest induced by ARID1B. In 
particular ARID1B cells with p21CIP1 ablation formed colonies with reduced cell size (Figure 4.14.1C). 
P53 knockdown fully suppressed ARID1B-mediated proliferative arrest (Figure 4.14.1A-C), and a 
similar result was observed when ARID1B was expressed alongside Human Papilloma virus (HPV) 
proteins E6/E7 (E6 alone conferred a partial rescue of ARID1B mediated arrest), suggesting that p53 
is important in ARID1B-mediated growth arrest (Figure 4.14.2).  
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4.15. Global changes in protein expression associated with ARID1B 
Mass spectrometry (MS)-based proteomics is a powerful tool to characterise changes in protein levels 
in different cell types. Here, SILAC was utilised to quantify global changes in protein levels upon 
ARID1B expression (Figure 4.15.1A). Protein identification and quantification was analysed as 
described in materials and methods and a total of 3312 proteins were detected above the threshold 
criteria. A protein density plot verified that there are changes in protein expression in IMR-90 cells 
expressing ARID1B, in both ‘forward’ and ‘reverse’ experiments (Figure 4.15.1A).  
 
Proteins with the highest fold increase in ARID1B expressing cells were components of the SASP 
(including GDF15, IGFBP7 and ICAM1) and a change was observed in several other senescence-
associated proteins (Figure 4.15.1B). Amongst the proteins that were downregulated in IMR-90 
expressing ARID1B, were a number of cell cycle proteins (including CDC2, PCNA and MCM2) (Figure 
4.15.1B). In corroboration with this Gene Ontology (GO) annotation showed that proteins associated 
with mitosis were negatively regulated by ARID1B expression (p-value 0.001) (Figure 4.15.1C). During 
senescence, cells increase the number of certain organelles including peroxisomes, lysosomes and 
mitochondria (Kurz et al., 2000; Lee et al., 2002b; Legakis et al., 2002). GSEA showed lysosomal 
proteins were highly enriched in ARID1B expressing cells (www.genome.jp/kegg/pathway), and 
proteins such as GLB1, LAMP1 and LAMP2 were all enriched more than 2.5 times (Figure 4.15.1C). 
 
Interestingly the levels of many mitochondrial proteins were higher in IMR-90 expressing ARID1B, as 
shown by GSEA (www.geneontology.org) (Figure 4.15.2A). Other gene sets enriched upon ARID1B 
expression were also mitochondria related; the most highly enriched pathways were oxidative 
phosphorylation (www.genome.jp/kegg/pathway) and electron transport chain (www.reactome.org) 
(Figure 4.15.2A, B).  As these processes are also altered in senescence, mitochondrial dysfunction 
may have a role in ARID1B mediated growth arrest (Hutter et al., 2004). In support of this hypothesis, 
ARID1B cells treated with the ROS scavenger N-acetyl-l-cysteine (NAC) proliferated faster than 
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4.16. ARID1B is deleted in cancer 
Recurrent mutations in ARID1B occur in specific pancreatic, hepatic, brain and breast cancers, such 
that the alterations are considered to be ‘driver mutations’ in these cancers (Fujimoto et al., 2012; 
Sausen et al., 2013; Shain et al., 2012; Stephens et al., 2012). In 2010, an extensive study 
cataloguing mutations in over 3000 cancer specimens was conducted (Beroukhim et al., 2010). Data 
from this study showed ARID1B was significantly deleted (but not significantly amplified) across all 54 
cancer types, and had a particularly high occurrence of deletion in breast and ovarian cancers (Table 
A4). Senescence is an important barrier to tumourigenesis in vivo, and ARID1B alterations frequently 
occur in particular cancers. Thus, ARID1B may be targeted for deletion to bypass senescence in pre-
cancerous cells. 
 
4.17. Conclusions and perspectives 
4.17.1. ARID1B depletion can bypass senescence through multiple mechanisms 
In the previous chapter, Arid1b was identified as a candidate regulator of replicative senescence. I 
then showed that knockdown of ARID1B extended the cellular lifespan of IMR90 and MEFs. Using the 
IMR-90 RAS:ER system of OIS I demonstrated that knockdown of ARID1B during OIS decreased the 
protein and mRNA levels of important senescence regulators p16INK4a and p21CIP1. 
 
To further elucidate how ARID1B controls senescence I compared the mRNA expression profile of 
vector and ARID1B knockdown IMR-90 ER:RAS cells treated with 4OHT as well as vector untreated 
control cells. The transcript levels of a number of SASP components and secreted factors increased 
when cells were treated with 4OHT including SPP1, MMP3, MMP10, GDF15, CFS2, CFS3, TNFAIP6, 
TNFSF18 and TNFSF15. Interestingly, these factors were significantly depleted in shARID1B cells 
treated with 4OHT compared to vector cells treated with 4OHT. The SWI/SNF complex has previously 
been linked to the regulation of secreted factors. In activated T-cells the BRG1-containing BAF 
complex binds to and regulates the IL-3/GM-CSF cytokine cluster in an NF-κB dependent manner 
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(Wurster et al., 2011). Furthermore, two independent groups have shown that SWI/SNF interacts with 
SMAD2/3 in response to TGFβ signalling and that this interaction activates SMAD2/3 target genes 
(Ross et al., 2006; Xi et al., 2008). In TGFβ stimulated cells, BRG1 depletion prevents cells from 
expressing a number of TGFβ-response genes including CTGF, BAMBI, SMAD7 and JMJD3 (Xi et al., 
2008). Importantly, The SWI/SNF sub-complex associated with activated SMAD2/3 contained core 
subunits BRG1, BAF155 and BAF170 and accessory subunit ARID1B (Xi et al., 2008). In a recent 
study gene expression profiling of ovarian cancer cells expressing wild-type ARID1A, showed that 
knockdown of ARID1A reduced the expression of senescence-related secreted factors IL-8, and 
GDF15 (Guan et al., 2011). Furthermore, ARID1A and BRG1 directly bound to the SMAD3 promoter, 
regulating SMAD3 gene expression (Guan et al., 2011). Therefore, it is likely that binding of SWI/SNF 
to these promoters is necessary for transcriptional regulation of secreted factors.  
 
As with other components of the SWI/SNF complex, ARID1B is known to regulate differentiation 
(Singhal et al., 2010; Yan et al., 2008). Interestingly our data showed that knockdown of ARID1B 
affected the expression of multiple differentiation associated genes belonging to the same gene family. 
Four members of the Late Cornified Envelope (LCE) gene cluster on chromosome 1q and two 
members of the Keratin-Associated Protein 2 (KRTAP2) gene cluster on chromosome 17q were 
significantly downregulated. KRTAP proteins are regulated by GR activation, and therefore depletion 
of KTRAP gene expression may be a result of aberrant SWI/SNF regulation of GR signalling (Donet et 
al., 2008).  Recently, KRTAP proteins have been linked to senescence and ageing. A microarray 
analysis comparing grey and black hair from individuals, identified greater than two fold expression of 
KRTAP in grey hair (Choi et al., 2011). Furthermore, the KRTAP13-3 promoter is significantly 
hypomethylated during replicative senescence; the loci is amongst six CpG methylation sites in the 
genome that undergo highly significant DNA-methylation changes during senescence (Koch et al., 
2012; Koch et al., 2013). Amongst the genes upregulated upon ARID1B depletion were ID1, ID2, ID3 
and ID4. ID1 is a negative regulator of INK4a expression and is strongly implicated in senescence 
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control (Alani et al., 2001; Ohtani et al., 2001). Deregulation of ID family proteins has been associated 
with cancer (Lasorella et al., 1996; Perk et al., 2005; Zebedee and Hara, 2001). 
 
The next step in elucidating the mechanism of ARID1B regulation would be to establish if ARID1B has 
a direct effect on the transcriptional regulation of particular senescence effectors such as p16INK4a and 
p21CIP1. Alternatively the changes in expression of these genes could be due to ARID1B regulating 
expression of specific transcription factors such as SMURF2, VDR or p53 which control INK4a and 
CDKN1a expression (Kong et al., 2011; Liu et al., 1996; Macleod et al., 1995; Saramaki et al., 2006; 
Tanaka et al., 2007). For this purpose it would be worthwhile to conduct ChIP analysis to identify 
ARID1B binding sites in senescent and non-senescent cells and also ARID1B knockdown cells as a 
control. 
 
PIK3CA is one of the most frequently mutated genes in cancer. Breast tumours with ARID1B 
mutations often contain mutations in PIK3CA and PTEN (Stephens et al., 2012), suggesting possible 
cooperation between ARID1B mutations and abrogated PI3K signalling during tumourigenesis. Thus I 
sought to investigate the relationship between ARID1B and PIK3CA. ARID1B depletion could bypass 
PIK3CAH1047R induced senescence and these cells had lower levels of p21CIP1 and p16INK4a. The 
SWI/SNF complex is linked to the PI3K/PTEN/AKT pathway through regulation of PTEN expression 
and direct interaction with AKT (Foster et al., 2006; Watanabe et al., 2011). Furthermore, I see an 
induction in protein expression of many SWI/SNF subunits during PIK3CAH1047R induced growth arrest 
(data not shown) suggesting SWI/SNF has a key role in PIK3CAH1047R mediated senescence.  
 
4.17.2. SWI/SNF proteins are induced during senescence 
As ARID1B was shown to be important in the maintenance of both replicative- and oncogene induced-
senescence, I next sought to identify how SWI/SNF is regulated during senescence. The mRNA levels 
of the majority of SWI/SNF components did not change during senescence. However I did observe an 
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increase in the protein level of ARID1B, BRG1, BRM and SNF5 during replicative senescence and 
ARID1A, ARID1B, BRG1, BRM and SNF5 during OIS. This is in agreement with recent findings 
showing that chromatin-associated BRG1 levels increase during OIS (Tu et al., 2013) and supports 
the concept that SWI/SNF proteins are important in the induction and maintenance of senescence. 
 
Interestingly I and others have observed that many SWI/SNF proteins are absent from mitotic cells. 
BRG1 and BRM are excluded from mitotic chromosomes, and BRM is partially degraded during 
mitosis (Muchardt et al., 1996; Sif et al., 1998). Similarly ARID1A is also degraded during mitosis, and 
I have observed exclusion of ARID1A, ARID1B and SNF5 from mitotic chromosomes (data not shown) 
(Flores-Alcantar et al., 2011). BRG1 and BRM are inactivated by phosphorylation during the G2/M 
transition. The resulting exclusion from chromatin may be important in halting transcription during 
mitosis (Muchardt et al., 1996).  
 
I next conducted SILAC-based quantitative proteomics to establish whether the composition of the 
SWI/SNF complex is significantly different in senescent cells. I performed SILAC-IPs to identify 
changes in proteins interacting with ARID1B in cells infected with either RASG12V or vector, or 
expressing ARID1B. The ARID1B IPs were specific, as all core SWI/SNF subunits (BRG1, BRM, 
SNF5, BAF155, BAF170) were detected in both experiments and enriched in ARID1B expressing 
cells. Furthermore, subunits that are known to be excluded from SWI/SNF-ARID1B complexes, 
including ARID1A and PBAF specific peptides (PBRM1, ARID2, BRD7, BAF45A) were not detected in 
ARID1B IPs however were present in a similar IP/MS experiment performed with BRG1 (data not 
shown). Interestingly, BAF specific subunit BAF45B was not detected in ARID1B or BRG1 IPs, 
confirming other reports that suggest it is exclusively expressed in post-mitotic neurons (Figure 4.17B) 
(Wu et al., 2007).  
A recent study of proteins associated with BRG1/BRM in T-cells described BCL7A-C, BCL11A-B, 
SS18 and BRD9 as permanent, un-exchangeable SWI/SNF subunits, as opposed to proteins that 
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temporarily interact with the complex (Kadoch and Crabtree, 2013; Kadoch et al., 2013). In the IPs for 
both ARID1B and BRG1 I detected BCL7A-C and SS18 however BCL11A-B and BRD9 was not 
detected, suggesting that although these proteins may bind to the SWI/SNF complex with a high 
affinity, the interaction may be stimulus or cell-type specific (Kadoch et al., 2013). 
 
Isoform exchange in the SWI/SNF complex is important in controlling specificity and function. Many 
SWI/SNF proteins are present as mutually exclusive exchangeable isoforms, including ARID1A and 
ARID1B. Ihave observed that overexpression of ARID1B causes ARID1A protein levels to decrease, 
however mRNA levels of ARID1A remain stable, suggesting levels of ARID1A and ARID1B are post-
translationally regulated and that free ARID1A or ARID1B proteins not integrated into the SWI/SNF 
complex are degraded. Such mechanisms controls the pool of SWI/SNF proteins available, including 
core components SNF5 and BRG1, as well as important accessory proteins such as BAF57 (Chen 
and Archer, 2005; Keppler and Archer, 2010; Sohn et al., 2007). 
 
Although I did not detect an exchange of particular SWI/SNF subunit isoforms during senescence, I 
did observe changes in SWI/SNF-associated proteins. Nucleolar proteins (KRI1, KRR1, RRP8, NO66, 
LYAR) were amongst the interactors highly enriched during OIS. This is particularly intriguing as 
myself as well as many others have observed by immunofluorescence that SWI/SNF components are 
not predominantly localised in the nucleoli (Muchardt et al., 1996; Reyes et al., 1997; Vradii et al., 
2006). This finding may be significant as there is a prominent change in nucleolar structure during 
OIS, the mechanism and reason for which are currently unknown (Narita et al., 2003a).  
 
SWI/SNF subunit BAF45D, KRI1 and NKRF preferentially bind to ARID1B in both RASG12V and 
ARID1B expressing cells compared to vector cells. The protein with the highest increase in ARID1B-
binding during senescence was KRI1. In C. elegans Kri-1 is linked to lifespan extension. Kri-1 binds to 
and promotes nuclear localisation of longevity regulator DAF16/FOXO (Berman and Kenyon, 2006). 
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DAF-16 controls lifespan in C. elegans by inhibiting insulin/IGF-1 signalling (Berman and Kenyon, 
2006; Kenyon, 2010). Recently it was shown that SWI/SNF is recruited to targeted DAF-16 promoters 
(Riedel et al., 2013). Although SWI/SNF subunits were identified as cofactors for DAF-16 function, a 
direct endogenous interaction between DAF-16 and SWI/SNF was not shown, suggesting they may be 
present within a larger complex (Riedel et al., 2013; Webb and Brunet, 2013). Considering this 
scenario, Kri-1 is a possible candidate to bridge the interaction between DAF-16 and SWI/SNF. 
 
Components of the ubiquitin mediated proteasome (UBR5, PSMD1 and PSMD2) were also detected 
binding to ARID1B. A previous study has shown that ARID1B acts as an E3 ubiquitin ligase targeting 
H2B Lys 119 for degradation (Li et al., 2010). However I have not observed any global changes in 
H2B ubiquitination upon ARID1B depletion or expression (data not shown). Other proteins interacting 
with ARID1B were associated with transcription and elongation, in support of previous evidence for a 
role of SWI/SNF in this process (Burrows et al., 2010; Drost et al., 2010).  
 
Proteins associated with senescence, previously identified as SWI/SNF interactors were not detected 
in the IPs; these include, RB1, p53 and SMAD2/3. This may be due to the difficulty in detecting 
phosphorylated proteins using SILAC LC-MS/MS. Sample preparation and instrumentation must be 
modified to detect proteins that exist in multiple phosphorylation states. In this study, I identified 
changes in ARID1B interactors during senescence. To further characterise the repertoire of SWI/SNF 
interactors in growing and senescent cells I could take advantage of an antibody that binds both BRG1 
and BRM. This will allow changes in the PBAF complex as well as ARID1A containing complexes to 
be studied. The JI antibody available from Crabtree and colleagues would be well suited for this 
purpose as it recognises the C-terminus of BRG1 and BRM and has been used to detect novel 
SWI/SNF binding partners in many studies (Dallas et al., 1998; Dunaief et al., 1994; Ho et al., 2009b; 
Kadoch and Crabtree, 2013; Khavari et al., 1993; Shanahan et al., 1999; Wurster et al., 2011; Zhao et 
al., 1998). 
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Proteins identified as SWI/SNF interactors by IP-MS must be verified by conducting reverse IPs or by 
validating immunoprecipitated proteins by western-blot. Density sedimentation analysis or glycerol 
gradients may be utilised to assess the stability of the protein interactions with SWI/SNF (Ho et al., 
2009b; Kadoch and Crabtree, 2013; Wang et al., 1996a). Previous studies have also used urea based 
denaturation methods to test the strength of protein interactions with core SWI/SNF subunits and in 
this way have identified novel SWI/SNF subunits (Kadoch and Crabtree, 2013). 
 
As ARID1B binds to a number of proteins involved in transcription and elongation I investigated the 
nuclear distribution of ARID1B to identify whether it is associated with active or repressed chromatin. 
In senescent cells, ARID1B was excluded from areas of repressed chromatin, particularly SAHFs, 
which are strongly marked with H3K9me3 and H3K27me3. Similarly, in proliferating cells ARID1B was 
excluded from replicating DNA (correlates with H3K27me3) identified by BrdU incorporation (Chandra 
et al., 2012). The observations suggest that ARID1B is associated with active chromatin regions. 
These observations are similar to findings that BRD7, a PBAF accessory component, is required for 
the establishment of OIS, however is excluded from SAHFs and is associated with actively transcribed 
chromatin (Drost et al., 2010; Staal et al., 2000). Furthermore, BRG1, BRM and SNF5 are similarly 
excluded from condensed chromatin and associated with highly transcribed chromatin (Reyes et al., 
1997). SWI/SNF may be important in the formation of active and repressed chromatin domains within 
the nucleus. In IMR-90 cells the formation of SAHFs during OIS is dependent on BRG1; in MEFs 
deletion of BRG1 causes a disruption in the formation of otherwise highly discrete heterochromatic 
domains (Bourgo et al., 2009; Tu et al., 2013).  
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4.17.3. Growth arrest induced by SWI/SNF is exerted through different mechanisms 
To further investigate the role of SWI/SNF in senescence, I used vectors expressing human isoforms 
of BRG1, BRM, ARID1A and ARID1B into the same vectors. Expression of the SWI/SNF proteins 
induced a premature growth arrest. Cells expressing BRG1, BRM, ARID1A or ARID1B possessed an 
enlarged flat morphology and had a lower percentage of BrdU incorporation. SWI/SNF protein 
expression also induced the formation of SAHFs and increased SA-β-Gal activity in cells.  
 
Expression of SWI/SNF proteins induces a growth arrest or a senescence response in multiple cell 
types (Drost et al., 2010; Dunaief et al., 1994; Guan et al., 2011; Inoue et al., 2011). One of the first 
studies identifying a role for SWI/SNF in senescence, showed that BRG1 bound to RB1 and HDAC1 
and repressed the transcription of E2F target genes (Dunaief et al., 1994). More recently BRG1 and 
other SWI/SNF proteins have been shown to bind to the CDKN1a and CDKN2a promoters (Kuwahara 
et al., 2010; Tu et al., 2013). SWI/SNF subunits also interact with p53 and co-operate in activating 
transcription of p53 target genes (Drost et al., 2010; Guan et al., 2011). In this work I show that 
expression of SWI/SNF subunits elevates p16INK4a and p21CIP1 levels.  
 
When we compare the effect of expressing individual SWI/SNF subunits, I found ARID1A infected 
cells have the highest p16INK4a induction and do not show an increase in p21CIP1 levels. P16INK4a 
mediated hyperphosphorylation of RB1 decreases the transactivation of E2F1 target genes including 
p21CIP1 and may explain why ARID1A expressing cells that have very high p16INK4a levels do not 
induce p21CIP1 expression (Gartel et al., 1998; Hiyama et al., 1998). ARID1A expressing cells also 
contain many distinctly formed SAHF, which act to repress E2F target genes (Narita et al., 2003a), 
supporting the notion that ARID1A mediated growth arrest is dependent on the p16INK4a/RB1 pathway. 
Conversely, ARID1B infected cells have less prominent SAHF formation, and have higher p21CIP1 
protein levels compared to ARID1A expressing cells. In HeLa cells, ectopic ARID1B expression 
increases p21CIP1 protein levels and ARID1B-SWI/SNF complexes are enriched at the CDKN1a 
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promoter compared with ARID1A-SWI/SNF complexes (Inoue et al., 2011; Ryme et al., 2009), 
supporting a role for ARID1B in p21CIP1 regulation. In contrast to this view, expression of ARID1A in 
HEC-1-A and OVISE cell lines containing ARID1A deletions induced p21CIP1 expression, suggesting 
that the function of SWI/SNF proteins is highly cell-type and context dependent (Euskirchen et al., 
2011; Wang et al., 1996b).   
 
To assess the contribution of important senescence effectors during ARID1B induced growth arrest, I 
co-infected young IMR-90 with either vector or ARID1B and with shRNAs targeting either p21CIP1, 
p16INK4a, p53 or an empty vector to act as a control. Knockdown of p21CIP1 and p16INK4a increased 
proliferation in ARID1B expressing cells, however p53 ablation conferred a full rescue of ARID1B 
mediated growth arrest, comparable to vector cells. Similarly, ARID1B cells co-expressing HPV E6/E7 
also had a proliferation rate higher than that of vector cells co-expressing HPV E6/E7, suggesting that 
p53 expression is important in ARID1B induced growth arrest. The observation that ARID1B 
expressing cells with p53 depletion proliferate faster than vector/shp53 cells could be due to the 
reduction in ARID1A protein levels in ARID1B expressing cells, and therefore there may be additional 
disruption of the p16INK4a/RB1 pathway. This decrease in ARID1A levels may confer a further 
proliferative advantage in ARID1B/shp53 cells. 
 
To understand the mechanism of senescence induction, global changes in protein levels were 
quantified in ARID1B expressing cells using SILAC. Amongst the proteins with the highest fold 
increase, were senescence-associated secreted factors GDF15, IGFBP7 and ICAM1. Lysosomal 
proteins associated with senescence were also induced upon ARID1B expression, including GLB1; 
the protein responsible for SA-β-gal activity (Lee et al., 2006). As expected, mitotic proteins were 
downregulated in ARID1B cells, suggesting these cells undergo cell cycle arrest. 
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Intriguingly, GSEA of SILAC data showed that the gene sets correlating with ARID1B expression are 
associated with mitochondrial dysfunction. There was a significant enrichment of proteins involved in 
oxidative phosphorylation and the electron transport chain. Mitochondrial production of reactive 
oxygen species (ROS) is known to contribute to the establishment of OIS (Lee et al., 1999; Moiseeva 
et al., 2009),and mitochondrial dysfunction plays a key role in replicative senescence and ageing 
(Hutter et al., 2004; Melov et al., 1999; Passos et al., 2007). Further investigation showed that the 
ROS scavenger N-acetyl-l-cysteine (NAC) suppressed the ARID1B mediated phenotype. Cells treated 
with NAC proliferated faster and appeared less flat and enlarged suggesting that ROS production 
mediates ARID1B induced growth arrest. 
 
It is of interest that both p53 ablation and ROS scavengers are able to rescue ARID1B mediated 
senescence, as these pathways are connected through numerous cellular processes, including 
mitochondrial dysfunction and apoptosis (Li et al., 2011b; Liu et al., 2008). Many studies have linked 
SWI/SNF to oxygen regulation. SWI/SNF is involved in the transactivation of hypoxia-inducible factor-
1α (HIF1α) in hypoxic conditions and SWI/SNF interacts with PPARγ coactivator-1α (PGC1α) to 
regulate mitochondrial fatty acid oxidation (Kenneth et al., 2009; Li et al., 2008). A recent study in 
yeast demonstrated that SWI/SNF proteins undergo rapid nuclear localisation in response to hypoxia 
and that many of the SWI/SNF target genes were involved in oxygen regulation (Dastidar et al., 2012).  
 
4.17.4. ARID1B exhibits tumour-suppressive functions in cancer 
The results presented in this work as well as work by others, demonstrates a link between various 
SWI/SNF proteins and senescence. Recently two elaborate studies cataloguing available exome 
sequencing data showed that, collectively, inactivating mutations in SWI/SNF subunits occur in around 
19% of all cancers, a frequency similar to TP53 (Kadoch et al., 2013; Shain and Pollack, 2013). As 
senescence acts as a barrier to tumour progression in vivo, mutations in SWI/SNF may drive cancer 
by inactivating senescence reinforcement programs.  
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ARID1B in particular is significantly deleted in cancers of the breast, pancreas, brain and liver 
(Fujimoto et al., 2012; Sausen et al., 2013; Shain et al., 2012; Stephens et al., 2012). In breast cancer 
ARID1B mutations are commonly associated with mutations in TP53 and PTEN (Stephens et al., 
2012). It would be of interest to analyse if this mutual inclusivity is true in other cancer genomes, in an 
attempt to shed light on the pathways cooperating during ARID1B mediated senescence. In 
agreement with our proposed mechanism of ARID1A-mediated senescence, reports have suggested 
that ARID1A and TP53 mutations are mutually exclusive (Bosse et al., 2013; Shain and Pollack, 2013; 
Wang et al., 2011). This mutual exclusivity however, is only seen in ovarian and gastric cancers and is 
not reported in other cancer types.   
 
ARID1B expression may also be deregulated at the epigenetic level in cancers. A recent study 
demonstrated that the ARID1B promoter was hypermethylated in multiple pancreatic cancer cell lines 
causing ARID1B transcriptional repression (Khursheed et al., 2013). The investigators next sought to 
identify the effect of ectopic ARID1B expression in these cell lines. Although they were able to detect 
an increase in ARID1B mRNA expression by RT-qPCR, they could not detect any increase in ARID1B 
protein expression (Khursheed et al., 2013). Ectopic ARID1B expression did not affect the proliferation 
of cells, however the ability to form colonies in soft agar was reduced and ARID1B expressing cells 
had higher levels of SA-β-gal activity (Khursheed et al., 2013). 
 
In the work presented, ARID1B was identified from a screening for regulators of senescence in MEFs, 
utilising a library containing genes frequently deleted in HCC. The HCC deletion library was thought to 
be enriched with potential tumour suppressors. It is therefore encouraging that mutations in ARID1B 
were recently described as ‘cancer driving’ in HCC (Fujimoto et al., 2012). Knockdown of ARID1B in 
some HCC cell lines increased cell proliferation by more than two-fold, however ARID1B knockdown 
had no effect in HCC cell lines when ARID1B was mutationally inactivated (Fujimoto et al., 2012). To 
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characterise the tumour suppressive role of ARID1B in HCC, it could be useful to ectopically express 
ARID1B in HCC cell lines that do not express ARID1B to see if this has a growth suppressive effect. 
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Chapter 5. Discussion & Future work 
5.1. Genetic screens are useful tools for identifying novel genes and 
pathways involved in senescence  
In the 50 years since senescence was first described by Hayflick and Moorhead, the field has 
progressed from what was once thought to be an exclusively in vitro phenomenon, to now being 
recognised as an important process involved in cancer and ageing  (Collado et al., 2007; Hayflick and 
Moorhead, 1961). Genetic screenings for the bypass of cellular senescence has led to the 
identification of novel cancer genes. ShRNA screenings are increasing in popularity as the method of 
choice for conducting screenings as they are less expensive and require less specialised laboratory 
equipment when compared to screenings using siRNAs. Recently, the use of NGS as a readout of 
bypass of senescence screenings has vastly increased the amount of data generated per screen. As 
the cost of NGS has progressively decreased and with technology rapidly improving, it is now easier to 
conduct screenings using genome wide shRNA libraries. The protocol established in this work is 
ideally suited for genome-wide screens based on the miR30 hairpin design. Genome-wide screens 
provide an un-biased method of identifying important genes, and possibly pathways, involved in 
establishing senescence.  
 
5.1.1. Genome-wide screening for regulators of OIS in IMR-90 
An example of such a genome-wide screening involves the use of the pGIPZ library to identify 
regulators of OIS.  The pGIPZ library consists of 60,000 shRNA constructs (Figure 5.1A). This library 
can be used to screen for regulators of OIS using the IMR-90 ER:RAS system. Addition of 4OHT to 
IMR-90 ER:RAS cells triggers OIS in a highly controlled manner and it is therefore a suitable system 
to use to set up a screen to identify OIS regulators (Acosta et al., 2008; Barradas et al., 2009). The 
advantage of using human fibroblasts is that they are not as prone to spontaneous mutations as MEFs 
and they have a longer replicative lifespan (Wu and Li, 1985). The ER:RAS system is preferred over 
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demonstrates that the level of library bias was minimal as shRNAs were evenly represented (Table 
A3). Furthermore, the most abundant shRNAs identified from sequencing were pool specific (shRNAs 
from pool 9 originate from plates (91-100) indicating that the level of cross-contamination between 
pools is also minimal.  
 
5.1.3. Set up of infection conditions for pGIPZ lentiviral screening 
The pGIPZ library is cloned into lentiviral vectors, which allows higher infection efficiencies to be 
achieved in target cells when compared to retroviral infection efficiencies. When using lentiviral 
vectors, infection conditions must be carefully controlled to minimise infection mediated cell stress or 
cytotoxicity, and alterations to cell physiology, which is a consequence of using high viral titers on 
primary cells.  
 
Infection conditions were optimised by testing transfection parameters to identify the best conditions 
for infection efficiency and cell viability. Amount of helper packaging plasmids psPAX2 and VSV-G, as 
well as viral dilution, were controlled to achieve optimal infection efficiencies (Figure 5.2B red 
asterisk). Higher infection efficiencies resulted in changes in cell morphology and cytotoxicity, and 
therefore an infection efficiency of 50% was deemed ideal to limit multiple infections and cell stress 
(Figure 5.2A). 
 
5.1.4. pGIPZ shp53-1 can be used as a control hairpin that bypasses OIS 
As with the lifespan extension screening in MEFs, a proof of principle experiment must first be 
conducted to assess the feasibility of a screening using a genome-wide shRNA library for bypass of 
OIS. For this end, a positive control shRNA able to bypass OIS must be selected. The control hairpin 
must be from the same vector backbone as constructs in the library to control for possible changes in 
infection efficiency and toxicity caused by using a control from a different vector backbone. I tested 6 
different shRNAs targeting either shp16 or shp53 alongside validated lentiviral constructs. I found that 
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the pGIPZ shRNAs produced a weak knockdown effect using the selected infection conditions (Figure 
5.3). The weak knockdown observed may be a result of a low MOI, however the infection conditions 
have been optimised such that the cells do not become stressed during infection and therefore the 
MOI should not be increased. A colony formation assay showed that pGIPZ shp53-1 was able to 
bypass OIS, and this hairpin should be used for further assay design experiments (Figure 5.3A, B). 
 
The pools size used for a genome wide screening will be larger than that of the HCC screen and 
therefore the proof of principle experiment must be more stringent to see if a bypass can take place. A 
preliminary colony formation assay showed that pGIPZ shp53 dilutions of 1:1000 did not result in an 
OIS bypass, however using the same dilutions of p156 RRL shp53 and pRS shp53 did produce an 
observable effect. An alternative method to assess the bypass of OIS in screening pools, is to 
measure proliferation rates and GFP enrichment during the screen. Samples which contain shRNAs 
able to bypass OIS will have higher proliferation rates, or a higher GFP positive population as 
uninfected cells (GFP negative) will not divide as rapidly; and these pools can be selected for 
sequencing. 
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5.2. ARID1B is an important senescence regulator 
In this work a genetic screen coupled to NGS was used to identify a component of the SWI/SNF 
complex ARID1B as a senescence regulator. Recently, a number of SWI/SNF components have been 
identified in screenings for bypass of senescence including PBRM1, BRD7 and SNF5 (Burrows et al., 
2010; Drost et al., 2010; Wajapeyee et al., 2008). In mammalian cells, a variety of SWI/SNF 
complexes exist, all of which use the energy generated by an integral ATPase subunit to remodel 
chromatin (Clapier and Cairns, 2009). The regulation of chromatin dynamics by the SWI/SNF complex 
is thought to play an essential role in many cellular processes including differentiation and proliferation 
 
ARID1B is a BAF-specific accessory component of the SWI/SNF complex. Previous work has shown 
that ARID1B has important cell cycle regulatory effects and controls the expression of cell cycle 
proteins p21CIP1 and c-myc, although its involvement in senescence has not been described (Inoue et 
al., 2011). SWI/SNF components have previously been implicated in senescence; however the 
mechanisms exerted by specific components differ depending on the conditions and cell types 
studied.  
 
In this study, a novel function of ARID1B in regulating senescence is described. I have shown that 
knockdown of ARID1B extends the cellular lifespan of both human and mouse fibroblasts and 
abrogates OIS induced by RASG12V and PIK3CAH1047R. During OIS, ARID1B ablation reduces the 
expression of important senescence effectors including p16INK4a and p21CIP1. Gene expression 
profiling of ARID1B-depleted cells during OIS, revealed that ARID1B regulated the expression of 
different gene families involved in differentiation, including the ID proteins that have an important role 
in oncogenesis and senescence regulation (Perk et al., 2005). This suggests, as others have seen, 
that ARID1B has a function during differentiation, and de-regulation of these pathways may have 
implications in tumourigenesis.  
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I observed a post-transcriptional increase in ARID1B and other SWI/SNF proteins during both 
replicative and oncogene-induced senescence, supporting the theory that these proteins are important 
senescence regulators. Pull-downs of ARID1B-associated complexes showed that a number of 
nucleolar proteins were enriched in senescent fractions compared to proliferating cells. I found that 
ARID1B bound to a number of proteins involved in transcription and elongation; in support of a role for 
ARID1B in this process, confocal imaging showed that ARID1B is excluded from areas of repressed 
chromatin, including SAHFs. 
  
Ectopic expression of SWI/SNF proteins ARID1A, ARID1B, BRG1 and BRM induced premature 
senescence as seen by a decrease in proliferation and an increase in senescence markers such as 
SAHFs and SA-β-gal activity. SAHFs were most prominent in ARID1A expressing cells and these cells 
had a high increase in p16INK4a expression, suggesting ARID1A-mediated senescence occurs via the 
activation of the p16INK4a/RB1 pathway. In ARID1B cells the increase in p16INK4a expression was 
moderate; however these cells had high levels of p21CIP1 expression. As knockdown of p53 was able 
to bypass ARID1B-induced growth arrest it suggests that ARID1B mediates senescence through the 
p53/p21CIP1 pathway. These findings imply, as others have proposed, that SWI/SNF proteins regulate 
senescence through multiple pathways.  
  
SILAC analysis of global changes in protein levels identified enrichment of mitochondrial proteins and 
depletion of mitotic proteins upon ARID1B expression. In particular proteins involved in oxidative 
phosphorylation and the electron transport chain were highly enriched. It was recently shown that cells 
undergoing BRAFV600E-induced senescence increase oxidative metabolism, which is essential for the 
maintenance of OIS (Kaplon et al., 2013). Higher levels of oxidative phosphorylation during OIS, 
results in the formation of ROS, which can also induce senescence (Lee et al., 1999; Moiseeva et al., 
2009). Mitochondrial dysfunction and ROS production are important features of the ARID1B-induced 
phenotype as treatment with antioxidant NAC suppressed growth arrest. 
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Deleterious mutations in ARID1B are present in  various cancer databases cataloguing mutations in 
human tumours and human cell lines. ARID1B mutations found in breast tumours are associated with 
mutations in other tumour suppressor genes including TP53 and PTEN (Stephens et al., 2012). Future 
work may focus on the effect of ectopically expressing these ARID1B mutants compared to wildtype 
ARID1B expression to determine if these mutants affect cell proliferation. Furthermore, it may be of 
interest to overexpress wildtype ARID1B in cell-lines harbouring deleterious ARID1B mutations to see 
if ARID1B expression can limit uncontrolled division in these cells. 
  
In addition, it will be important to carefully analyse genes regulated by ARID1B from the microarray 
and SILAC data, and establish if ARID1B affects the expression of these genes by altering histone 
modifications or nucleosome positioning at these loci. For this purpose ChIP and MNase-mapping 
assays may be conducted to elucidate the mechanism of ARID1B-mediated senescence. 
  
5.3. The SWI/SNF complex is implicated in cancer and ageing 
The data presented so far has identified a role for SWI/SNF proteins in replicative senescence and 
OIS in vitro. As previously discussed SWI/SNF proteins are implicated in ageing and cancer in vivo. 
The first report linking the SWI/SNF complex to ageing showed that a BRM-RB1-C/EBPα complex 
forms in old rat and mouse livers, but not in young livers, and promotes growth arrest (Iakova et al., 
2003). Furthermore, the work suggests the increase of BRM is responsible for the weak proliferative 
response to partial hepatectomy in aged livers and therefore suppresses liver regeneration (Iakova et 
al., 2003)  
 
More recently, the SWI/SNF-BAF complex has been linked to longevity in C. elegans (Riedel et al., 
2013). In mutant strains where insulin signalling is blocked, SWI/SNF associates with longevity factor 
DAF-16/FOXO and this interaction is necessary for promoting stress resistance and lifespan extension 
(Riedel et al., 2013). Although forkhead box proteins regulate senescence in mammalian cells, no 
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interaction between FOXO proteins and SWI/SNF has been observed, both in our studies and others 
(Courtois-Cox et al., 2006; Kyoung Kim et al., 2005; Li et al., 2013; Wang et al., 1996b). Indeed the 
work in C. elegans did not demonstrate a direct interaction between the endogenous proteins (Riedel 
et al., 2013). Furthermore, the association between SWI/SNF and DAF-16 was only seen in stressful 
conditions, suggesting that other factors, which may be activated by particular stimuli only, are 
required to recruit SWI/SNF to DAF-16 promoters (Riedel et al., 2013; Webb and Brunet, 2013). 
 
In human cancers, mutations in SWI/SNF subunits occur more frequently than mutations in any other 
chromatin remodelling complex (Kadoch et al., 2013). This has led to the belief that particular 
components of the SWI/SNF complex are bona fide tumour suppressors (Vogelstein et al., 2013). 
Importantly, it appears loss of one SWI/SNF allele is sufficient to promote the formation of aggressive 
cancers whereas other tumour suppressor genes often undergo loss of heterozygosity (LOH) in both 
alleles in tumours (Jones et al., 2010; Kadoch et al., 2013; Varela et al., 2011; Versteege et al., 1998). 
Extensive analysis of available tumour exome sequencing data, has revealed that mutations in 
SWI/SNF components are generally inactivating and target the core subunits and the DNA-binding 
accessory proteins (Shain and Pollack, 2013). 
  
Further support that SWI/SNF acts as a tumour-suppressor complex has hailed from results showing 
that overexpression of SWI/SNF proteins in cell-lines harbouring inactivating SWI/SNF mutations, 
suppressed cell division. This was first seen when reintroduction of BRG1 into the SW13 cancer cell 
line induced senescence, and similarly ectopically expressing SNF5 in MRT cell lines results in a G1 
cell cycle arrest (Dunaief et al., 1994; Versteege et al., 2002). More recently, overexpression of 
ARID1A in OCC cell lines with ARID1A deletion also induced a G1 arrest (Guan et al., 2011). 
  
In vivo, mice injected with OSE4 cells expressing shArid1a developed large tumours, when compared 
to mice injected with OSE4 cells expressing shGFP (Guan et al., 2011). Similarly, many groups have 
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shown that Snf5 null mice rapidly develop aggressive tumours, similar to human MRT, suggesting that 
mutations in SWI/SNF genes are drivers of cancers, rather than passenger mutations (Guidi et al., 
2001; Roberts et al., 2000; Roberts et al., 2002). These results together with our data showing that 
SWI/SNF are important regulators of senescence, suggests that targeted mutations in SWI/SNF 
proteins may favour the bypass of senescence in pre-cancerous cells. 
 
Epigenetic silencing of SWI/SNF genes also leads to loss of expression. The catalytic subunit BRM is 
frequently silenced by an unknown post-transcriptional mechanism, and silencing is restored by the 
use of HDAC inhibitors (Glaros et al., 2007; Yamamichi et al., 2005). In pancreatic cancer cell lines, 
ARID1B is frequently silenced by promoter hypermethylation; expression can also be restored by 
using HDAC inhibitors, providing a therapeutic window of opportunity in tumours where SWI/SNF 
components are epigenetically silenced (Khursheed et al., 2013).  
 
5.4. The clinical utility of targeting the SWI/SNF complex in cancer 
detection and therapy 
As mutations in SWI/SNF subunits have a significant role in the progression of particular tumours, loss 
of expression of these SWI/SNF components may be used as a biomarker for carcinogenesis (Jones 
et al., 2010; Varela et al., 2011; Versteege et al., 1998; Wang et al., 2011). A number of studies have 
proposed that the expression pattern of SWI/SNF subunits can be used as biomarkers of certain 
disease states (da Costa et al., 2013; Li et al., 2011a; Oike et al., 2013). For example, there is a 
significant reduction in SNF5 expression in metastatic melanoma compared with dysplastic nevi, 
suggesting that loss of SNF5 correlates with the loss of the senescent state (Lin et al., 2009; Mooi and 
Peeper, 2006). Furthermore negative SNF5 expression correlated with metastasis, poor patient 
survival and an increased resistance to chemotherapy, and therefore SNF5 expression may be used 
to predict the response to treatment and survival in patients with melanoma (Li et al., 2011a; Lin et al., 
2009; Moore et al., 2012).  
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Loss of PBRM1 expression occurs in approximately 40-70% of clear cell renal cell carcinoma (ccRCC) 
and is associated with advanced tumour stage and poor patient prognosis (da Costa et al., 2013; 
Numata et al., 2013; Pawlowski et al., 2013; Varela et al., 2011). Thus PBRM1 expression is a 
promising biomarker for predicting survival outcome, however further work is needed before it can be 
used clinically to enable personalised therapy (Poste, 2011; Vasudev et al., 2012). Similarly in ovarian 
clear cell carcinoma (OCCC), ARID1A mutations occur in more than 50% of tumours, and loss of 
ARID1A expression is an early event in the development of OCCC from endometriosis (Jones et al., 
2010; Yamamoto et al., 2012a, b). Further studies have assessed the value of using ARID1A as a 
biomarker in OCCC however as with PBRM1, this is yet to be followed up in a clinical setting (Kobel et 
al., 2013; Samartzis et al., 2012).  
 
Interestingly, mutations in either ARID1A or ARID1B occur in approximately 11% of neuroblastomas, 
however structural rearrangements in ARID1B occur at a much higher frequency (Sausen et al., 
2013). Sausen et al. reported that in 74 primary tumours and cell lines studied, at least one structural 
alteration was detected at the MYCN, ARID1B or ALK loci in all tumours (Sausen et al., 2013). These 
rearrangements can be detected from circulating tumour DNA in the blood and may be used as 
biomarkers of neuroblastoma as they are not present in normal cells (Sausen et al., 2013). Since 
neuroblastoma is a highly aggressive cancer with low patient survival outcomes, it has been proposed 
that detection of these chromosomal rearrangements can be used as a non-invasive method to 
identify residual disease, following surgery (Morgenstern et al., 2013; Sausen et al., 2013). 
 
It has been proposed that epigenetic alterations may substitute for genomic instability in the 
progression of lethal cancers (McKenna and Roberts, 2009; Wilson et al., 2010). SNF5 deficient 
cancers are highly aggressive however tumour cells appear genomically stable, diploid and 
predominantly devoid of other mutations (McKenna et al., 2008). In contrast to genetic mutations, 
epigenetic modifications are reversible, and therefore are strong candidates for therapeutic 
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intervention in cancers driven by mutations in a single epigenetic regulator (Rodriguez-Paredes and 
Esteller, 2011). Indeed, specific inhibitors targeting chromatin remodelling proteins have been 
successful in preclinical trials and multiple drugs are currently into phase III clinical trials (Helin and 
Dhanak, 2013).  
 
As SWI/SNF mutations are largely inactivating and involve the deregulation of multiple survival 
pathways; efforts are focused on targeting these cancers by synthetic lethality (C.W.M. Roberts 
unpublished data, (Oike et al., 2013)). Alternatively therapies may be designed to target downstream 
effectors that are hyperactivated by SWI/SNF loss. In particular a number of studies have shown that 
the SWI/SNF complex antagonises Polycomb activity, and inhibiting EZH2 in these cancers reduces 
tumour growth (Wilson et al., 2010; Young and Jacks, 2010). EZH2 is the catalytic component of the 
PRC2 complex, and is overexpressed in a number of cancers (Bachmann et al., 2006; Kleer et al., 
2003; Varambally et al., 2002). Recently, specific chemical EZH2 inhibitors have been designed and 
tested for their anti-proliferative response in different cancers (McCabe et al., 2012), (Knutson et al., 
2012; Qi et al., 2012). For some haematological and solid cancers EZH2 inhibitors have already 
entered clinical trials, including EPZ-6438 from Epizyme. Of interest, MRT with inactivated SNF5 are 
selectively killed upon treatment with EPZ-6438 (Knutson et al., 2013). Furthermore administration of 
EPZ-6438 to SNF5 null mice results in complete MRT regression (Knutson et al., 2013). 
 
As the field progresses, future work must focus on elucidating the precise mechanism caused by 
SWI/SNF inactivation in cancer subtypes. This will allow highly specific drugs to be designed with the 
potential to increase efficacy and reduce side effects in patients. Furthermore, the use of biomarkers 
will permit personalised treatment opportunities and better prediction of responsiveness to certain 
drugs. These therapies will not only be useful in cancers with a high percentage of somatic SWI/SNF 
mutations, but also in cases where the targeting mechanism of the entire SWI/SNF complex is 
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disrupted, for example by fusion to oncogenic proteins (Kadoch and Crabtree, 2013) or by interaction 
with long non-coding RNAs (Prensner et al., 2013). 
 
5.5. Concluding remark 
 Through the efforts of cancer genome sequencing, SWI/SNF proteins have now been recognised as 
bona fide tumour suppressors. Focus is currently being shifted into better understanding the 
mechanism of SWI/SNF tumour suppressive actions. Indeed in the last few years our knowledge of 
SWI/SNF subunits has vastly expanded, and many novel functions of the complex have been 
discovered. The precise mechanism of recruitment of these complexes to chromatin remains unclear, 
and may involve histone modifications or interactions with specific transcription factors or other 
proteins. SWI/SNF interacts with many cancer regulators including proteins involved in the DDR, 
nuclear hormone receptor signalling and tumour suppressor proteins p53 and RB1 (Figure 1.11).  
  
What is most striking about the mutations of SWI/SNF proteins in cancer is that certain subunits are 
highly mutated exclusively in a particular cancer type, suggesting that the function of SWI/SNF is truly 
dependent on environmental cues and cell types studied. In our work I showed that ectopic expression 
of SWI/SNF subunits ARID1A, ARID1B, BRG1 and BRM induced premature senescence. Functional 
redundancy between these mutually exclusive SWI/SNF subunits is not frequently observed; however 
many SWI/SNF subunits have been linked to activation of the same tumour suppressive programs, 
namely the p53/p21CIP1 and p16INK4a/RB1 pathways (Bultman et al., 2000; Nagl et al., 2007; Wilson 
and Roberts, 2011). 
  
Taken together, the work presented here and by others reveals the importance of SWI/SNF proteins in 
the induction and maintenance of senescence. Further work is needed to understand the exact 
contributions of particular SWI/SNF subunits in senescence, and therefore expand our understanding 
of the roles of this highly diverse complex in cancer and ageing. This will aid the development of 
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targeted therapies, which is currently hindered by the lack of mechanistic understanding by which 
epigenetic mutations promote tumourigenesis. Fully realising the function that epigenetic regulators, 
such as ARID1B, have on tumour progression could result in more specific and effective drugs for the 
treatment of cancers principally driven by reversible epigenetic instability. 
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Table A5. cDNA constructs. 
Vector  cDNA Antibiotic resistance Addgene reference 
pBABE Empty Vector Puromycin - 
pGIPZ Empty Vector Puromycin - 
LXSN Empty Vector Puromycin - 
pRS Empty Vector Puromycin - 
pBABE GFP Puromycin - 
pBABE RASG12V Puromycin - 
pBABE ARID1A Puromycin - 
pBABE ARID1B Puromycin - 
pLNC RAS:ER Neomycin - 
pLPC Cherry Puromycin - 
LXSN E6 Puromycin - 
LXSN E7 Puromycin - 
LXSN E6/E7 Puromycin - 
pLNCX PIK3CAH1047R Neomycin 25635 
pBABE BRG1 Puromycin 1959 
pBABE BRM Puromycin 1961 
 
Table A6. shRNA target sequences. 
Construct Target sequence 
MLP m-shp53   CACTACAAGTACATGTGTA 
MLP m-shp16/Arf CCGCTGGGTGCTCTTTGTGT 
pRS m-shArid1b AAGGCGAAAGATTACCTCAAA 
pRS shARID1B-1 CACAACCAGTCTTGAAACAAA 
pRS shARID1B-2 AAGCAAATTGACTTTAAAGAA 
pRS shARID1B-3 ACCATGAAGACTTGAACTTAA 
pRS shp16 GAGGAGGTGCGGGCGCTGC 
pRS shp53  GTAGATTACCACTGGAGTC  
pRS shp21 TCCCACAATGCTGAATATACA 
pGIPZ shp53-1 TAACTGCAAGAACATTTCT 
pGIPZ shp53-2 TACACATGTAGTTGTAGTG 
pGIPZ shp53-3 TCTCTTCCTCTGTGCGCCG 
pGIPZ shp16-1 TGCCCATCATCATCACCTG 
pGIPZ shp16-2 ACACAAAGAGCACCCAGCG 
pGIPZ shp16-3 TGAGCTGAAGCTATGCCCG 
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Table A7. Solexa PCR primers. 
Primer Sequence (5’ to 3’) 
p5 miR3' aatgatacggcgaccaccgactaaagtagccccttg 
p7 Loop primer caagcagaagacggcatacgatagtgaagccacaga 
Solexa barcode 1 caagcagaagacggcatacgaaaatagtgaagccacaga 
Solexa barcode 2 caagcagaagacggcatacgaaactagtgaagccacaga 
Solexa barcode 3 caagcagaagacggcatacgaaagtagtgaagccacaga 
Solexa barcode 4 caagcagaagacggcatacgaaattagtgaagccacaga 
Solexa barcode 5 caagcagaagacggcatacgaacatagtgaagccacaga 
Solexa barcode 6 caagcagaagacggcatacgaacctagtgaagccacaga 
Solexa barcode 7 caagcagaagacggcatacgaacgtagtgaagccacaga 
Solexa barcode 8 caagcagaagacggcatacgaacttagtgaagccacaga 
Solexa barcode 9 caagcagaagacggcatacgaagatagtgaagccacaga 
Solexa barcode 10 caagcagaagacggcatacgaagctagtgaagccacaga 
Solexa barcode 11 caagcagaagacggcatacgaaggtagtgaagccacaga 
Solexa barcode 12 caagcagaagacggcatacgaagttagtgaagccacaga 
Solexa barcode 13 caagcagaagacggcatacgaatatagtgaagccacaga 
Solexa barcode 14 caagcagaagacggcatacgaatctagtgaagccacaga 
Solexa barcode 15 caagcagaagacggcatacgaatgtagtgaagccacaga 
 
Table A8. Sequencing primers 
Primer Sequence (5’ to 3’) 
pBABE F  CTTTATCCAGCCCTCAC  
pBABE R  ACCCTAACTGACACACATTC  
pRS F GCTGACGTCATCAACCCGCT 
pRS R TGTGAGGGACAGGGGAG 
Solexa primer TAGCCCCTTGAATTCCGAGGCAGTAGGCA 
pGIPZ F TGGAAACACTTGCTGGGATT 
pGIPZ R  GCTCCTAAAGTAGCCCCTTG 
 
Table A9. RT-qPCR primers. 
Target gene Sequence (5’ to3’) 
ARID1A CCCCTCAATGACCTCCAGTA 
 CTGGAAATCCCTGATGTGCT 
Arid1b CCTGGAAAATCCAACCATGA 
 GTCTACAAGCAGCCAGGGAG 
ARID1B CTGTCGCCTCAGAGAC 
 GTTCGATAAAAGCGCCAT 
ARID2 CTGGCGCTGTCCTGCCATGT 
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 CAGCGGTGTCTGTTGGGCAGT 
β-GUS CTCATTTGGAATTTTGCCGATT 
 CCGAGTGAAGATCCCCTTTTTA 
BAF155 GGGCCTTTGGCCTACCAGCC 
 CAGATGCCACGCGAGGGTCC 
BAF170 GGAATGGGTACGACCAGTCA 
 CATCTTCCACAGATGCCTCA 
BRD7 GCTCCTGGCTACTCCATGAT 
 TCATTCCTGAGTGCAACAGC 
BRG1 CATCACCCCCATCCAGAA 
 CTCAATGGTCGCTTTGGTTC 
CDKN1a CCTGTCACTGTCTTGTACCCT 
 GCGTTTGGAGTGGTAGAAATCT 
E2F7  GGAAAGGCAACAGCAAACTCT 
 TGGGAGAGCACCAAGAGTAGAAGA 
GDF15 AGGGCGGCCCGAGAGATACG 
 AGTGCTGCTGAAGGAGATGCCTGA 
INHBA GCTGTTCCTGACTCGGCAAACGT 
 GGATACTCACGCCAGAAGTGCGG 
INK4a CGGTCGGAGGCCGATCCAG  
 GCGCCGTGGAGCAGCAGCAGCT 
INK4B GAATGCGCGAGGAGAACAAG 
 CCATCATCATGACCTGGATCG 
LCE2A CACCCAAGTGTCCTCCAAAG 
 CCCCAGAAGGTTCACACTCA 
LCE2B  CCGACTGCTGTGAGAGTGAA 
 TTGAGGTGCTCCATCAAGTG 
P53 CCGCAGTCAGATCCTAGCG 
 AATCATCCATTGCTTGGGACG 
PBRM1 GTGTGATGAACCAAGGAGTGGC 
 GATATGGAGGTGGTGCCTGCTG 
PGC1a GGCAGGCCTCAGATCTAAAAGTCA 
 GCATCATGGGAGCCTTCTTGTC 
Rps14  GACCAAGACCCCTGGACCT 
 CCCCTTTTCTTCGAGTGCTA 
SMARCB1 GGATGGCAACGATGAGAAGT 
 CTGTTCCTCTTGGCCTTCTG 
SPP1 TTGCAGCCTTCTCAGCCAA 
 CAAAAGCAAATCACTGCAATTCTC 
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 Table A10. Primers for cloning. 
Primer Sequence (5’ to 3’) 
ARID1B SalI forward cagagagaaagctctggGTCGACcgatacc 
ARID1B SalI reverse ggGTCGACtcataactgcccaatctgaaacagtacatca 
Lumican BamH1 forward acctgGGATTCatttgccaaaaatgagtctaagtgc 
Lumican EcoR1 reverse acctgGAATTCttaattaagagtgactt 
 
Table A11. Antibodies. 
Target Clone/Lot Company Catalogue no. Source Application 
ARID1B A301-047A-1 Bethyl A301-047A Rabbit IF, IP 
ARID1B M01 Abgent AT1189a Mouse IF 
ARID1B R06587 Sigma HPA016511 Rabbit IF 
ARID1A M01 Abgent AT1188a Mouse IF 
SNF5 R07906 Sigma HPA018248 Rabbit IF 
BRG1 1147182 abcam ab4081 Rabbit IF, IP 
BRM GR5208-2 abcam ab15597 Rabbit IF 
BrdU PRB-1 Invitrogen A21303 Mouse IF 
p16INK4a JC-8 Santa Cruz sc-56330 Mouse IF 
p21Waf1/Cip1 12D1 Cell Signaling  2947 Rabbit IF 
p53 DO-1 Santa Cruz sc-126 Mouse IF 
P-AKT Ser473 193H12 Cell Signaling  4085 Rabbit IF 
IgG control GR63825-D abcam ab46540 Rabbit IP 
H3K27me3 JBC1873477 Millipore 07-449 Rabbit IF 
H3K9me3 1971290 Millipore 07-442 Rabbit IF 
P-AKT Ser473 193H12 Cell Signaling  4085 Rabbit IF 
Anti-Mouse IgG Alexa Fluor® 488 Invitrogen A11029 Goat IF 
Anti-Mouse IgG Alexa Fluor® 594 Invitrogen A11032 Goat IF 
Anti-Rabbit IgG Alexa Fluor® 488 Invitrogen A11034 Goat IF 
Anti-Rabbit IgG Alexa Fluor® 594 Invitrogen A11037 Goat IF 
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